<?xml version="1.0"?>
<sample>
<topic id="PHP226" outputclass="drug" type="drug" namespace="/drugs/dicobalt-edetate" basename="dicobalt-edetate">
  <title>DICOBALT EDETATE</title>
  <body>
    <data name="vtmid">317870009</data>
    <p outputclass="interactionsLinks">List of individual interactants: <xref format="dita" href="#bnf_int_88">Codeine</xref>, <xref format="dita" href="#bnf_int_59">Paracetamol</xref></p>
    <p outputclass="constituentDrugs">The properties listed below are those particular to the combination only. For the properties of the components please consider, <xref format="dita" href="#PHP3619">rifampicin</xref>, <xref format="dita" href="#PHP3604">ethambutol hydrochloride</xref>, <xref format="dita" href="#PHP3608">isoniazid</xref>, <xref format="dita" href="#PHP3612">pyrazinamide</xref>, <xref format="dita" href="#PHP3619">rifampicin</xref>.</p>
    <data name="classifications">
      <data name="classification">
        <data name="drugClassification">PHP106980:116</data>
      </data>

      <data name="classification">
          <data name="drugClassification">PHP106980:116</data>

        <data name="inheritsFromClass">PHP34650</data>
        <data name="inheritsFromClass">PHP34623</data>
        <data name="inheritsFromClass">PHP34648</data>
        <data name="inheritsFromClass">PHP34550</data>
      </data>
      <data name="classification">
          <data name="drugClassification">PHP106980:116</data>
      </data>
    </data>
    <data name="primaryDomainOfEffect">
      <data name="domainOfEffect">cardiovascular system
        <data name="primaryTherapeuticUse"><data name="therapeuticUse">blood pressure conditions
            <data name="therapeuticUse">hypertension</data>
          </data></data>
        <data name="secondaryTherapeuticUses"><data name="therapeuticUse">heart failure</data></data>
      </data>
    </data>
    <data name="secondaryDomainsOfEffect">
      <data name="domainOfEffect">respiratory system
        <data name="primaryTherapeuticUse"><data name="therapeuticUse">airways disease, obstructive</data></data>
      </data>
      <data name="domainOfEffect">skin
        <data name="primaryTherapeuticUse"><data name="therapeuticUse">unknown</data></data>
        <data name="secondaryTherapeuticUses"><data name="therapeuticUse">inflammatory skin conditions
            <data name="therapeuticUse">eczema and psoriasis</data>
          </data></data>
      </data>
      <data name="domainOfEffect">nose
        <data name="primaryTherapeuticUse"><data name="therapeuticUse">rhinitis</data></data>
      </data>
      <data name="domainOfEffect">oropharynx
        <data name="primaryTherapeuticUse"><data name="therapeuticUse">oral ulceration and inflammation</data></data>
      </data>
    </data>
    <p outputclass="synonyms">Sodium Lactate Intravenous Infusion, Compound; Compound; Hartmann&#x2019;s Solution for Injection; Ringer-Lactate Solution for Injection</p>
  </body>
  <topic id="PHP55181" outputclass="indicationsAndDose">
    <title>Indications and dose</title>
    <body>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Anaerobic infections</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1 month</p>
            <p>
7.5&#x202F;mg/kg every 12&#x202F;hours usually treated for 7 days (for 10&#x2013;14 days in
<i>Clostridium difficile</i>
infection).
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 2 months&#x2013;11 years</p>
            <p>
7.5&#x202F;mg/kg every 8&#x202F;hours (max. per dose 400&#x202F;mg) usually treated for 7 days (for 10&#x2013;14 days in
<i>Clostridium difficile</i>
infection).
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 12&#x2013;17 years</p>
            <p>400&#x202F;mg every 8&#x202F;hours.</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
400&#x202F;mg every 8&#x202F;hours, alternatively 500&#x202F;mg every 8&#x202F;hours usually treated for 7 days (for 10&#x2013;14 days in
<i>Clostridium difficile</i>
infection).
</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By rectum</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;11 months</p>
            <p>
125&#x202F;mg 3 times a day for 3 days, then 125&#x202F;mg twice daily, for usual total treatment duration of 7 days.
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;4 years</p>
            <p>
250&#x202F;mg 3 times a day for 3 days, then 250&#x202F;mg twice daily, for usual total treatment duration of 7 days.
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 5&#x2013;9 years</p>
            <p>
500&#x202F;mg 3 times a day for 3 days, then 500&#x202F;mg twice daily, for usual total treatment duration of 7 days.
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10&#x2013;17 years</p>
            <p>
1&#x202F;g 3 times a day for 3 days, then 1&#x202F;g twice daily, for usual total treatment duration of 7 days.
</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
1&#x202F;g 3 times a day for 3 days, then 1&#x202F;g twice daily, for usual total treatment duration of 7 days.
</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By intravenous infusion</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
500&#x202F;mg every 8&#x202F;hours usually treated for 7 days (for 10&#x2013;14 days in
<i>Clostridium difficile</i>
infection), to be given over 20 minutes.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication"><ph outputclass="organism"><i>Helicobacter pylori</i></ph>
eradication; in combination with clarithromycin and esomeprazole; or in combination with clarithromycin and lansoprazole; or in combination with amoxicillin and lansoprazole; or in combination with clarithromycin and omeprazole; or in combination with clarithromycin and pantoprazole; or in combination with clarithromycin and rabeprazole
</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>400&#x202F;mg twice daily.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication"><ph outputclass="organism"><i>Helicobacter pylori</i></ph>
eradication; in combination with amoxicillin and omeprazole
</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>400&#x202F;mg 3 times a day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication"><ph outputclass="organism"><i>Helicobacter pylori</i></ph>
eradication failure (two-week regimen comprising a proton pump inhibitor plus tripotassium dicitratobismuthate plus tetracycline)
</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>400&#x2013;500&#x202F;mg 3 times a day for 2 weeks.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Fistulating Crohn's disease</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
10&#x2013;20&#x202F;mg/kg daily in divided doses, usual dose 400&#x2013;500&#x202F;mg 3 times a day usually given for 1 month but no longer than 3 months because of concerns about peripheral neuropathy.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Leg ulcers and pressure sores</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>400&#x202F;mg every 8&#x202F;hours for 7 days.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">
Bacterial vaginosis (notably
<ph outputclass="organism"><i>Gardnerella vaginalis</i></ph>
infection)
</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
400&#x2013;500&#x202F;mg twice daily for 5&#x2013;7 days, alternatively 2&#x202F;g for 1 dose.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Bacterial vaginosis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By vagina using vaginal gel</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
1&#x202F;applicatorful daily for 5 days, dose to be administered at night.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pelvic inflammatory disease</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>400&#x202F;mg twice daily for 14 days.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Acute ulcerative gingivitis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;2 years</p>
            <p>50&#x202F;mg every 8&#x202F;hours for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 3&#x2013;6 years</p>
            <p>100&#x202F;mg every 12&#x202F;hours for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7&#x2013;9 years</p>
            <p>100&#x202F;mg every 8&#x202F;hours for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10&#x2013;17 years</p>
            <p>200&#x2013;250&#x202F;mg every 8&#x202F;hours for 3 days.</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>200&#x2013;250&#x202F;mg every 8&#x202F;hours for 3 days.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Acute oral infections</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;2 years</p>
            <p>50&#x202F;mg every 8&#x202F;hours for 3&#x2013;7 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 3&#x2013;6 years</p>
            <p>100&#x202F;mg every 12&#x202F;hours for 3&#x2013;7 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7&#x2013;9 years</p>
            <p>100&#x202F;mg every 8&#x202F;hours for 3&#x2013;7 days.</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>200&#x202F;mg every 8&#x202F;hours for 3&#x2013;7 days.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Surgical prophylaxis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
400&#x2013;500&#x202F;mg, to be administered 2 hours before surgery, then 400&#x2013;500&#x202F;mg every 8&#x202F;hours if required for up to 3 doses (in high-risk procedures).
</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By rectum</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
1&#x202F;g, to be administered 2 hours before surgery, then 1&#x202F;g every 8&#x202F;hours if required for up to 3 doses (in high-risk procedures).
</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By intravenous infusion</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
500&#x202F;mg, to be administered up to 30 minutes before the procedure (if rectal administration inappropriate), then 500&#x202F;mg every 8&#x202F;hours if required for up to 3 doses (in high-risk procedures).
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Invasive intestinal amoebiasis</p>
          <p outputclass="therapeuticIndication">
Extra-intestinal amoebiasis (including liver abscess)
</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;2 years</p>
            <p>
200&#x202F;mg 3 times a day for 5 days in intestinal infection (for 5&#x2013;10 days in extra-intestinal infection).
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 3&#x2013;6 years</p>
            <p>
200&#x202F;mg 4 times a day for 5 days in intestinal infection (for 5&#x2013;10 days in extra-intestinal infection).
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7&#x2013;9 years</p>
            <p>
400&#x202F;mg 3 times a day for 5 days in intestinal infection (for 5&#x2013;10 days in extra-intestinal infection).
</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10&#x2013;17 years</p>
            <p>
800&#x202F;mg 3 times a day for 5 days in intestinal infection (for 5&#x2013;10 days in extra-intestinal infection).
</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
800&#x202F;mg 3 times a day for 5 days in intestinal infection (for 5&#x2013;10 days in extra-intestinal infection).
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Urogenital trichomoniasis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;2 years</p>
            <p>50&#x202F;mg 3 times a day for 7 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 3&#x2013;6 years</p>
            <p>100&#x202F;mg twice daily for 7 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7&#x2013;9 years</p>
            <p>100&#x202F;mg 3 times a day for 7 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10&#x2013;17 years</p>
            <p>
200&#x202F;mg 3 times a day for 7 days, alternatively 400&#x2013;500&#x202F;mg twice daily for 5&#x2013;7 days, alternatively 2&#x202F;g for 1 dose.
</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
200&#x202F;mg 3 times a day for 7 days, alternatively 400&#x2013;500&#x202F;mg twice daily for 5&#x2013;7 days, alternatively 2&#x202F;g for 1 dose.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Giardiasis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 1&#x2013;2 years</p>
            <p>500&#x202F;mg once daily for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 3&#x2013;6 years</p>
            <p>600&#x2013;800&#x202F;mg once daily for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7&#x2013;9 years</p>
            <p>1&#x202F;g once daily for 3 days.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10&#x2013;17 years</p>
            <p>
2&#x202F;g once daily for 3 days, alternatively 400&#x202F;mg 3 times a day for 5 days, alternatively 500&#x202F;mg twice daily for 7&#x2013;10 days.
</p>
          </li>
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>
2&#x202F;g once daily for 3 days, alternatively 400&#x202F;mg 3 times a day for 5 days, alternatively 500&#x202F;mg twice daily for 7&#x2013;10 days.
</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Established case of tetanus</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By intravenous infusion</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>(consult product literature).</p>
          </li>
        </ul>
      </section>
      <!-- Always come after indicationAndDoseGroups -->
      <section outputclass="doseAdjustments">
        <title>Dose adjustments due to interactions</title>
        <sectiondiv>
          <p>Dose adjustment may be necessary if smoking started or stopped during treatment.</p>
        </sectiondiv>
      </section>
      <section outputclass="doseEquivalence">
        <title>Dose equivalence and conversion</title>
        <p>2 puffs is equivalent to 5&#x202F;micrograms.</p>
      </section>
      <section outputclass="extremesOfBodyWeight">
        <title>Doses at extremes of body-weight</title>
        <p>To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal weight for height.</p>
      </section>
      <section outputclass="pharmacokinetics">
        <title>Pharmacokinetics</title>
        <p>Aminophylline is a stable mixture or combination of theophylline and ethylenediamine; the ethylenediamine confers greater solubility in water.</p>
        <p>Theophylline is metabolised in the liver. The plasma-theophylline concentration is increased in heart failure, hepatic impairment, and in viral infections. The plasma-theophylline concentration is decreased in smokers, and by alcohol consumption. Differences in the half-life of aminophylline are important because the toxic dose is close to the therapeutic dose.</p>
      </section>
      <section outputclass="potency">
        <title>Potency</title>
        <p>Fluticasone cream 0.05%: potent.</p>
        <p>Fluticasone ointment 0.005%: potent.</p>
      </section>
    </body>
  </topic>
  <topic id="PHP48870" outputclass="interactions">
    <title>Interactions</title>
    <body>
      <section outputclass="general">
        <sectiondiv>
          <p>Appendix 1 (paracetamol).</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47397" outputclass="pregnancy">
    <title>Pregnancy</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">systemic</ph>
use
</p>
          <p>
Avoid unless the potential benefit outweighs the risk.
</p>
          <p>
Avoid during the third trimester (risk of closure of fetal ductus arteriosus
<i>in utero</i>
and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">topical</ph>
use in adults
</p>
          <p>
Patient packs for topical preparations carry a warning to avoid during pregnancy.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP39960" outputclass="hepaticImpairment">
    <title>Hepatic impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use
</p>
          <p>
Reduce
<i>oral</i>
dose in moderate impairment.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">injectable</ph>
use
</p>
          <p>
Reduce
<i>intravenous dose</i>
in severe impairment.
</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use
</p>
          <p>
Avoid
<i>oral</i>
use in severe impairment.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>Consult product literature.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP38138" outputclass="renalImpairment">
    <title>Renal impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use in adults
</p>
          <p><i>
Co-amoxiclav 250/125 tablets or 500/125 tablets
</i>
: if eGFR 10&#x2013;30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
, one
<i>250/125</i>
strength tablet every 12 hours or one
<i>500/125</i>
strength tablet every 12 hours; if eGFR less than 10&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
, one
<i>250/125</i>
strength tablet every 24 hours or one
<i>500/125</i>
strength tablet every 24 hours.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in adults
</p>
          <p><i>Co-amoxiclav injection</i>
(expressed as co-amoxiclav): if eGFR 10&#x2013;30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
, 1.2&#x202F;g initially, then 600&#x202F;mg every 12 hours; if eGFR less than 10&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
, 1.2&#x202F;g initially, then 600&#x202F;mg every 24 hours.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use in children
</p>
          <p><i>Co-amoxiclav 125/31 suspension</i>
,
<i>
250/62 suspension, 250/125 tablets, or 500/125 tablets
</i>
: use normal dose every 12 hours if estimated glomerular filtration rate 10&#x2013;30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
. Use the normal dose recommended for mild or moderate infections every 12 hours if estimated glomerular filtration rate less than 10&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in children
</p>
          <p><i>Co-amoxiclav injection</i>
: use normal initial dose and then use half normal dose every 12 hours if estimated glomerular filtration rate 10&#x2013;30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
; use normal initial dose and then use half normal dose every 24 hours if estimated glomerular filtration rate less than 10&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
.
</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p>
Risk of crystalluria with high doses (particularly during parenteral therapy).
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use
</p>
          <p>
Accumulation of electrolytes contained in parenteral preparations can occur in patients with renal failure.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use in adults
</p>
          <p><i>Co-amoxiclav 400/57 suspension</i>
: avoid if eGFR less than 30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use in children
</p>
          <p><i>Co-amoxiclav 400/57 suspension</i>
: avoid if estimated glomerular filtration rate less than 30&#x202F;mL/minute/1.73&#x202F;m
<sup>2</sup>
.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP57378" outputclass="contraindications">
    <title>Contra-indications</title>
    <body>
      <section outputclass="contraindications">
        <p>
          <ph outputclass="contraindication">Children under 2 years except on specialist advice (safety of such use has not been established)</ph>(in children);<ph outputclass="contraindication">epilepsy</ph>;<ph outputclass="contraindication">hepatic dysfunction</ph>;<ph outputclass="contraindication">history of narrow angle glaucoma</ph>;<ph outputclass="contraindication">hypothyroidism</ph>;<ph outputclass="contraindication">many antihistamines should be avoided in<xref format="dita" href="#PHP78608" type="bookmark">Acute porphyrias</xref>but alimemazine is thought to be safe</ph>;<ph outputclass="contraindication">myasthenia gravis</ph>;<ph outputclass="contraindication">neonate (due to significant antimuscarinic activity)</ph>(in neonates);<ph outputclass="contraindication">Parkinson's disease</ph>;<ph outputclass="contraindication">phaeochromocytoma</ph>;<ph outputclass="contraindication">prostatic hypertrophy</ph>(in adults);<ph outputclass="contraindication">renal dysfunction</ph>;<ph outputclass="contraindication"><xref format="dita" href="#PHP78608" type="bookmark">Acute porphyrias</xref></ph>
        </p>
      </section>
    </body>
  </topic>
  <topic id="PHP57687" outputclass="sideEffects">
    <title>Side-effects</title>
    <body>
      <section outputclass="frequencies">
        <sectiondiv outputclass="rare">
          <p outputclass="title">Rare</p>
          <sectiondiv outputclass="sideEffects">
            <p><ph outputclass="sideEffect">Anaphylaxis</ph>
;
<ph outputclass="sideEffect">angioedema</ph>
;
<ph outputclass="sideEffect">bronchospasm</ph>
;
<ph outputclass="sideEffect">hypersensitivity reactions</ph>
</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="notKnown">
          <p outputclass="title">Frequency not known</p>
          <sectiondiv outputclass="sideEffects">
            <p><ph outputclass="sideEffect">Acute dystonia</ph>
;
<ph outputclass="sideEffect">agitation</ph>
;
<ph outputclass="sideEffect">agranulocytosis</ph>
;
<ph outputclass="sideEffect">akathisia</ph>
;
<ph outputclass="sideEffect">akinesia</ph>
;
<ph outputclass="sideEffect">angle-closure glaucoma</ph>
;
<ph outputclass="sideEffect">anti-muscarinic effects</ph>
;
<ph outputclass="sideEffect">
arrhythmias (may be predisposed by hypokalaemia and cardiac disease)
</ph>
;
<ph outputclass="sideEffect">blurred vision</ph>
;
<ph outputclass="sideEffect">contact sensitisation</ph>
;
<ph outputclass="sideEffect">convulsions</ph>
;
<ph outputclass="sideEffect">drowsiness</ph>
;
<ph outputclass="sideEffect">dry mouth</ph>
;
<ph outputclass="sideEffect">dyskinesia</ph>
;
<ph outputclass="sideEffect">gastro-intestinal disturbances</ph>
;
<ph outputclass="sideEffect">headache</ph>
;
<ph outputclass="sideEffect">hyperprolactinaemia</ph>
;
<ph outputclass="sideEffect">hypotension</ph>
;
<ph outputclass="sideEffect">insomnia</ph>
;
<ph outputclass="sideEffect">jaundice</ph>
;
<ph outputclass="sideEffect">leukopenia (on prolonged high dose)</ph>
;
<ph outputclass="sideEffect">nasal stuffiness</ph>
;
<ph outputclass="sideEffect">neuroleptic malignant syndrome</ph>
;
<ph outputclass="sideEffect">ocular changes</ph>
;
<ph outputclass="sideEffect">pallor</ph>
(in children);
<ph outputclass="sideEffect">paradoxical excitement</ph>
;
<ph outputclass="sideEffect">parkinsonism</ph>
;
<ph outputclass="sideEffect">photosensitivity</ph>
;
<ph outputclass="sideEffect">postural hypotension (in elderly)</ph>
(in adults);
<ph outputclass="sideEffect">
postural hypotension (in volume depletion)
</ph>
;
<ph outputclass="sideEffect">rashes</ph>
;
<ph outputclass="sideEffect">respiratory depression</ph>
;
<ph outputclass="sideEffect">rigidity</ph>
;
<ph outputclass="sideEffect">
tardive dyskinesia (usually after prolonged high doses)
</ph>
;
<ph outputclass="sideEffect">tremor</ph>
;
<ph outputclass="sideEffect">urinary retention</ph>
</p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="sideEffectsAdvice">
        <title>Side-effects, further information</title>
        <sectiondiv>
          <p>
Patients on high dosage may develop photosensitivity and should avoid exposure to direct sunlight.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In adults</p>
          <p>
Elderly patients are more susceptible to side-effects.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>
Children are more susceptible to side-effects.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In adults</p>
          <p>
Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely, especially with high doses or in children and the elderly. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>
Drowsiness is a significant side-effect with most of the older antihistamines although paradoxical stimulation may occur rarely in children, especially with high doses. Drowsiness may diminish after a few days of treatment and is considerably less of a problem with the newer antihistamines.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP46848" outputclass="directionsForAdministration">
    <title>Directions for administration</title>
    <body>
      <section>
        <sectiondiv>
          <p>
Acidic beverages, such as coffee or fruit juice, may decrease the absorption of nicotine through the buccal mucosa and should be avoided for 15 minutes before the use of oral nicotine replacement therapy.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by transdermal patch</p>
          <p>
Patches should be applied on waking to dry, non-hairy skin on the hip, trunk, or upper arm and held in position for 10&#x2013;20 seconds to ensure adhesion; place next patch on a different area and avoid using the same site for several days.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by nasal spray</p>
          <p>
Initially 1 spray should be used in both nostrils but when withdrawing from therapy, the dose can be gradually reduced to 1 spray in 1 nostril.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by oral spray</p>
          <p>
The oral spray should be released into the mouth, holding the spray as close to the mouth as possible and avoiding the lips. The patient should not inhale while spraying and avoid swallowing for a few seconds after use. If using the oral spray for the first time, or if unit not used for 2 or more days, prime the unit before administration.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by sublingual tablet</p>
          <p>
Each tablet should be placed under the tongue and allowed to dissolve.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by lozenge</p>
          <p>
Slowly allow each lozenge to dissolve in the mouth; periodically move the lozenge from one side of the mouth to the other. Lozenges last for 10&#x2013;30 minutes, depending on their size.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by inhalation</p>
          <p>
Insert the cartridge into the device and draw in air through the mouthpiece; each session can last for approximately 5 minutes. The amount of nicotine from 1 puff of the cartridge is less than that from a cigarette, therefore it is necessary to inhale more often than when smoking a cigarette. A single 10&#x202F;mg cartridge lasts for approximately 20 minutes of intense use; a single 15&#x202F;mg cartridge lasts for approximately 40 minutes of intense use.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Administration by medicated chewing gum</p>
          <p>
Chew the gum until the taste becomes strong, then rest it between the cheek and gum; when the taste starts to fade, repeat this process. One piece of gum lasts for approximately 30 minutes.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP72877" outputclass="patientAndCarerAdvice">
    <title>Patient and carer advice</title>
    <body>
      <section outputclass="adviceAroundMissedDoses">
        <title>Missed doses</title>
        <sectiondiv>
          <p>
When used as an oral contraceptive, the following advice is recommended &#x2018;If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days&#x2019;.
</p>
          <p>
The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.
</p>
        </sectiondiv>
      </section>
      <section outputclass="generalPatientAdvice">
        <sectiondiv>
          <p outputclass="title">
Diarrhoea and vomiting with use as an oral contraceptive
</p>
          <p>
Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use for
<ph outputclass="indication">Contraception</ph>
</p>
          <p outputclass="title">Starting routine</p>
          <p>
One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment.
</p>
          <sectiondiv>
            <p outputclass="title">
Changing from a combined oral contraceptive
</p>
            <p>
Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).
</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="title">After childbirth</p>
            <p>
Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.
</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv>
          <p>
Counsel women to seek medical attention promptly in case of significant symptoms, especially pain.
</p>
          <p>Patient counselling advised.</p>
          <p>
Patient information leaflet to be provided.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use for
<ph outputclass="indication">Emergency contraception</ph>
</p>
          <p>
If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use for
<ph outputclass="indication">Emergency contraception</ph>
</p>
          <ul>
            <li>
When prescribing or supplying hormonal emergency contraception, women should be advised:
</li>
            <li>that their next period may be early or late;</li>
            <li>
that a barrier method of contraception needs to be used until the next period;
</li>
            <li>
to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;
</li>
            <li>
to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).
</li>
          </ul>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP63317" outputclass="nationalFunding">
    <title>National funding/access decisions</title>
    <body>
      <section>
        <sectiondiv outputclass="niceTechnologyAppraisals">
          <p outputclass="title">NICE technology appraisals (TAs)</p>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA130</p>
            <sectiondiv>
              <p outputclass="title">
Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis (October 2007)
</p>
              <p>
The tumour necrosis factor alpha (TNF-&#x3B1;) inhibitor infliximab is an option for the treatment of adults with active rheumatoid arthritis who have failed to respond to at least 2 disease-modifying antirheumatic drugs (DMARDs), including methotrexate (unless contra-indicated). TNF-&#x3B1; inhibitors should be given in combination with methotrexate.
</p>
              <p>
Infliximab should be withdrawn if response is not adequate within 6 months. Response to treatment should be monitored at least every 6 months in patients who respond initially; treatment should be withdrawn if response is not maintained. An alternative TNF-&#x3B1; inhibitor may be considered for patients in whom treatment is withdrawn because of intolerance before the initial 6-month assessment of efficacy.
</p>
              <p>
Use of TNF-&#x3B1; inhibitors for the treatment of severe, active, and progressive rheumatoid arthritis in adults not previously treated with methotrexate or other DMARDs is not recommended.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA130">www.nice.org.uk/TA130</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA134</p>
            <sectiondiv>
              <p outputclass="title">
Infliximab for plaque psoriasis in adults (January 2008)
</p>
              <p>
Infliximab is recommended for the treatment of very severe plaque psoriasis which has failed to respond to standard systemic treatments (including ciclosporin and methotrexate) or to photochemotherapy, or when standard treatments cannot be used because of intolerance or contra-indications. Infliximab should be withdrawn if the response is not adequate after 10 weeks.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA134">www.nice.org.uk/TA134</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA143</p>
            <sectiondiv>
              <p outputclass="title">
Adalimumab, etanercept, and infliximab for the treatment of ankylosing spondylitis (May 2008)
</p>
              <p>
Infliximab is not recommended for the treatment of ankylosing spondylitis. Patients who are already receiving infliximab for the treatment of ankylosing spondylitis can continue treatment until they and their specialist consider it appropriate to stop.
</p>
              <p>
See full NICE guidance for specific criteria to diagnose severe active ankylosing spondylitis, confirm sustained active spinal disease, and assess response to treatment.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA143">www.nice.org.uk/TA143</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA163</p>
            <sectiondiv>
              <p outputclass="title">
Infliximab for acute exacerbations of ulcerative colitis (December 2008)
</p>
              <p>
Infliximab is recommended as an option for the treatment of acute exacerbations of severe ulcerative colitis when treatment with ciclosporin is contra-indicated or inappropriate.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA163">www.nice.org.uk/TA163</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA187</p>
            <sectiondiv>
              <p outputclass="title">
Infliximab and adalimumab for Crohn&#x2019;s disease (May 2010)
</p>
              <p>
Infliximab is recommended for the treatment of severe active Crohn&#x2019;s disease that has not responded to conventional therapy (including corticosteroids and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications; infliximab can also be used in a similar way in children over 6 years of age. In adults over 18 years of age, infliximab is recommended for the treatment of fistulating Crohn&#x2019;s disease that has not responded to conventional therapy (including antibacterials, drainage, and other drugs affecting the immune response) or when conventional therapy cannot be used because of intolerance or contraindications.
</p>
              <p>
Infliximab should be given as a planned course of treatment for 12 months or until treatment failure, whichever is shorter. Treatment should be continued beyond 12 months only if there is evidence of active disease&#x2014;in these cases the need for treatment should be reviewed at least annually. If the disease relapses after stopping treatment, infliximab can be restarted.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA187">www.nice.org.uk/TA187</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA195</p>
            <sectiondiv>
              <p outputclass="title">
Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (August 2010)
</p>
              <p>
Infliximab, in combination with methotrexate, is an option for the treatment of severe active rheumatoid arthritis in adults who have had an inadequate response to, or have an intolerance of, other DMARDs including at least 1 TNF inhibitor, and who cannot use rituximab because of contra-indications or intolerance. Treatment should be continued only if there is adequate response. Patients should be monitored at least every 6 months.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA195">www.nice.org.uk/TA195</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA199</p>
            <sectiondiv>
              <p outputclass="title">
Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (August 2010)
</p>
              <p>
Infliximab is recommended for the treatment of active and progressive psoriatic arthritis in adults who have peripheral arthritis with at least 3 tender joints and at least 3 swollen joints, and who have not responded adequately to at least 2 standard disease-modifying antirheumatic drugs (used alone or in combination).
</p>
              <p>
Infliximab should be discontinued if there is an inadequate response at 12 weeks.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA199">www.nice.org.uk/TA199</xref>
          </sectiondiv>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA329</p>
            <sectiondiv>
              <p outputclass="title">
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
</p>
              <p>
Infliximab is an option for treating moderately to severely active ulcerative colitis in adults whose disease has responded inadequately to conventional therapy including corticosteroids and mercaptopurine or azathioprine, or in adults who are intolerant to or have contra-indications for conventional therapies.
</p>
              <p>
The choice of treatment should be made on an individual basis and if more than one treatment is suitable, the least expensive should be chosen.
</p>
              <p>
Infliximab should be given as a planned course of treatment until treatment fails (including the need for surgery) or until 12 months after starting treatment, whichever is shorter. Treatment should be continued only if there is clear evidence of a response. Patients who continue treatment should be reassessed at least every 12 months to determine whether ongoing treatment is still clinically appropriate.
</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA329">www.nice.org.uk/TA329</xref>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP48084" outputclass="drugAction">
    <title>Drug action</title>
    <body>
      <section>
        <sectiondiv>
          <p>
Ezetimibe inhibits the intestinal absorption of cholesterol.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
If used alone, it has a modest effect on lowering LDL-cholesterol, with little effect on other lipoproteins.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP73558" outputclass="importantSafetyInformation">
    <title>Important safety information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="title">NSAIDs and cardiovascular events</p>
          <p>
All NSAID use (including cyclo-oxygenase-2 selective inhibitors) can, to varying degrees, be associated with a small increased risk of thrombotic events (e.g. myocardial infarction and stroke) independent of baseline cardiovascular risk factors or duration of NSAID use; however, the greatest risk may be in those receiving high doses long term.
</p>
          <p><b>Cyclo-oxygenase-2 selective inhibitors</b>
,
<b>diclofenac</b>
(150&#x202F;mg daily) and
<b>ibuprofen</b>
(2.4&#x202F;g daily) are associated with an increased risk of thrombotic events. The increased risk for diclofenac is similar to that of licensed doses of
<b>etoricoxib</b>
.
<b>Naproxen</b>
(1&#x202F;g daily) is associated with a lower thrombotic risk, and low doses of ibuprofen (1.2&#x202F;g daily or less) have not been associated with an increased risk of myocardial infarction.
</p>
          <p>
The lowest effective dose of NSAID should be prescribed for the shortest period of time to control symptoms and the need for long-term treatment should be reviewed periodically.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">NSAIDs and gastro-intestinal events</p>
          <p>
All NSAIDs are associated with serious gastro-intestinal toxicity; the risk is higher in the elderly. Evidence on the relative safety of non-selective NSAIDs indicates differences in the risks of serious upper gastro-intestinal side-effects&#x2014;piroxicam, ketoprofen, and ketorolac are associated with the highest risk; indometacin, diclofenac, and naproxen are associated with intermediate risk, and ibuprofen with the lowest risk (although high doses of ibuprofen have been associated with intermediate risk).
<b>
Selective inhibitors of cyclo-oxygenase-2
</b>
are associated with a
<i>lower risk</i>
of serious upper gastro-intestinal side-effects than non-selective NSAIDs.
</p>
          <p>
Recommendations are that NSAIDs associated with a low risk e.g. ibuprofen are
<i>generally preferred</i>
, to start at the
<i>lowest recommended dose</i>
and not to use more than one oral NSAID at a time.
</p>
          <p>
The combination of a NSAID and low-dose aspirin can increase the risk of gastro-intestinal side-effects; this combination should be used only if absolutely necessary and the patient should be monitored closely.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Asthma</p>
          <p>
Any degree of worsening of asthma may be related to the ingestion of NSAIDs, either prescribed or (in the case of ibuprofen and others) purchased over the counter.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP42938" outputclass="cautions">
    <title>Cautions</title>
    <body>
      <section outputclass="cautions">
        <title>General cautions:</title>
        <p>
          <ph outputclass="caution">Heart failure</ph>
        </p>
        <sectiondiv outputclass="additionalCautions">
          <p outputclass="title">Specific cautions:</p>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p><ph outputclass="caution">allergic disorders</ph>;<ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph>;<ph outputclass="caution">cerebrovascular disease</ph>;<ph outputclass="caution">coagulation defects</ph>;<ph outputclass="caution">connective-tissue disorders</ph>;<ph outputclass="caution">Crohn&#x2019;s disease (may be exacerbated)</ph>;<ph outputclass="caution">epilepsy</ph>;<ph outputclass="caution">ischaemic heart disease</ph>;<ph outputclass="caution">peripheral arterial disease</ph>;<ph outputclass="caution">psychiatric disturbances</ph>;
<ph outputclass="caution">risk factors for cardiovascular events</ph>;<ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph>;<ph outputclass="caution">uncontrolled hypertension</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With rectal use</p>
            <p><ph outputclass="caution">allergic disorders</ph>;<ph outputclass="caution">avoid rectal administration in haemorrhoids</ph>;<ph outputclass="caution">avoid rectal administration in proctitis</ph>;<ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph>;<ph outputclass="caution">cerebrovascular disease</ph>;<ph outputclass="caution">coagulation defects</ph>;<ph outputclass="caution">connective-tissue disorders</ph>;<ph outputclass="caution">Crohn&#x2019;s disease (may be exacerbated)</ph>;<ph outputclass="caution">epilepsy</ph>;<ph outputclass="caution">ischaemic heart disease</ph>;<ph outputclass="caution">peripheral arterial disease</ph>;<ph outputclass="caution">psychiatric disturbances</ph>;<ph outputclass="caution">risk factors for cardiovascular events</ph>;<ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph>;<ph outputclass="caution">uncontrolled hypertension</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With systemic use</p>
            <p><ph outputclass="caution">elderly (risk of serious side-effects and fatalities)</ph>;<ph outputclass="caution">parkinsonism</ph></p>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP70510" outputclass="conceptionAndContraception">
    <title>Conception and contraception</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p>
When ulipristal is given as an emergency contraceptive the effectiveness of combined hormonal and progestogen-only contraceptives may be reduced&#x2014;additional precautions (barrier methods) required for 14 days for combined and parenteral progestogen-only hormonal contraceptives (16 days for
<i>Qlaira</i>
<tm tmtype="reg"/>
) and 9 days for oral progestogen-only contraceptives.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
When ulipristal is given for uterine fibroids non-hormonal contraceptive methods (barrier methods or intra-uterine device) should be used both during treatment and for 12 days after stopping, if required.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP50063" outputclass="pregnancy">
    <title>Pregnancy</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p>
There is limited evidence for the safe use of zafirlukast during pregnancy; however, it can be taken as normal in women who have shown a significant improvement in asthma not achievable with other drugs before becoming pregnant.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
It is particularly important that asthma should be well controlled during pregnancy. Women planning to become pregnant should be counselled about the importance of taking their asthma medication regularly to maintain good control.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
Manufacturer advises use only if potential benefit outweighs risk.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP38928" outputclass="monitoringRequirements">
    <title>Monitoring requirements</title>
    <body>
      <section outputclass="therapeuticDrugMonitoring">
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intramuscular</ph>
use or
<ph outputclass="route">intravenous</ph>
use in adults
</p>
          <p>
For multiple daily dose regimen, one-hour (&#x2018;peak&#x2019;) serum concentration should be 5&#x2013;10&#x202F;mg/litre; pre-dose (&#x2018;trough&#x2019;) concentration should be less than 2&#x202F;mg/litre.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In adults</p>
          <p>
For multiple daily dose regimen in endocarditis, one-hour (&#x2018;peak&#x2019;) serum concentration should be 3&#x2013;5&#x202F;mg/litre; pre-dose (&#x2018;trough&#x2019;) concentration should be less than 1&#x202F;mg/litre. Serum-gentamicin concentration should be measured after 3 or 4 doses, then at least every 3 days and after a dose change (more frequently in renal impairment).
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in adults
</p>
          <p>
For once-daily dose regimen, consult local guidelines on monitoring serum-gentamicin concentration.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in neonates
</p>
          <p>
Extended interval dose regimen in neonates: pre-dose (&#x2018;trough&#x2019;) concentration should be less than 2&#x202F;mg/litre (less than 1&#x202F;mg/litre if more than 3 doses administered); consider monitoring one hour (&#x2018;peak&#x2019;) concentration in neonates with poor response to treatment, with oedema, with Gram-negative infection, or with birth-weight greater than 4.5&#x202F;kg (consider increasing dose if &#x2018;peak&#x2019; concentration less than 8&#x202F;mg/litre in severe sepsis).
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in children
</p>
          <p>
Once daily dose regimen: pre-dose (&#x2018;trough&#x2019;) concentration should be less than 1&#x202F;mg/litre.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intramuscular</ph>
use or
<ph outputclass="route">intravenous</ph>
use in children
</p>
          <p>
Multiple daily dose regimen: one hour (&#x2018;peak&#x2019;) serum concentration should be 5&#x2013;10&#x202F;mg/litre ; pre-dose (&#x2018;trough&#x2019;) concentration should be less than 2&#x202F;mg/litre.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>
Multiple daily dose regimen for endocarditis: one hour (&#x2018;peak&#x2019;) serum concentration should be 3&#x2013;5&#x202F;mg/litre; pre-dose (&#x2018;trough&#x2019;) concentration should be less than 1&#x202F;mg/litre. Serum-gentamicin concentration should be determined twice each week (more often in renal impairment).
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intramuscular</ph>
use or
<ph outputclass="route">intravenous</ph>
use in children
</p>
          <p>
Multiple daily dose regimen for cystic fibrosis: one hour (&#x2018;peak&#x2019;) serum concentration should be 8&#x2013;12&#x202F;mg/litre; pre-dose (&#x2018;trough&#x2019;) concentration should be less than 2&#x202F;mg/litre.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intrathecal</ph>
use or
<ph outputclass="route">intraventricular</ph>
use in children
</p>
          <p>
Intrathecal/intraventricular injection: cerebrospinal fluid concentration should not exceed 10&#x202F;mg/litre.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP56212" outputclass="unlicensedUse">
    <title>Unlicensed use</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>Not licensed for use in hyperkalaemia.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">oral</ph>
use in children
</p>
          <p>
Syrup and tablets not licensed for use in children under 2 years.
</p>
          <p>
Modified-release tablets not licensed for use in children under 3 years.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use or
<ph outputclass="route">subcutaneous</ph>
use in children
</p>
          <p>
Injection and solution for intravenous infusion not licensed for use in children under 12 years.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intravenous</ph>
use in children
</p>
          <p>
Administration of undiluted salbutamol injection through a central venous catheter is not licensed.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP57821" outputclass="prescribingAndDispensingInformation">
    <title>Prescribing and dispensing information</title>
    <body>
      <section>
        <sectiondiv>
          <p>
Co-careldopa is a mixture of carbidopa and levodopa; the proportions are expressed in the form x/y where x and y are the strengths in milligrams of carbidopa and levodopa respectively.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
When transferring patients from another levodopa/dopa-decarboxylase inhibitor preparation, the previous preparation should be discontinued at least 12 hours before.
</p>
          <p>
Co-careldopa 25/100 provides an adequate dose of carbidopa when low doses of levodopa are needed.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
2 tablets
<i>Sinemet</i>
<tm tmtype="reg"/>
12.5&#x202F;mg/50&#x202F;mg &#x2261; 1 tablet
<i>Sinemet</i>
<tm tmtype="reg"/>
Plus 25&#x202F;mg/100&#x202F;mg.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP34962" outputclass="treatmentCessation">
    <title>Treatment cessation</title>
    <body>
      <section>
        <sectiondiv>
          <p>
Associated with a higher risk of withdrawal effects compared with other antidepressants.
</p>
        </sectiondiv>
        <sectiondiv>
          <p>
Gastro-intestinal disturbances, headache, anxiety, dizziness, paraesthesia, tremor, sleep disturbances, and sweating are most common features of withdrawal if treatment stopped abruptly or if dose reduced markedly; dose should be reduced over several weeks.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP58881" outputclass="handlingAndStorage">
    <title>Handling and storage</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">topical</ph>
use
</p>
          <p>
Wash hands immediately after use (or wash hands 30 minutes after application if hands treated).
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">transdermal</ph>
use
</p>
          <p>
Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection).
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP89072" outputclass="lessSuitableForPrescribing">
    <title>Less suitable for prescribing</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">
When used by
<ph outputclass="route">eye</ph>
</p>
          <p>
Betamethsone with neomycin eye-drops are less suitable for prescribing.
</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
With
<ph outputclass="route">intranasal</ph>
use
</p>
          <p>
Betamethsone with neomycin nasal-drops are less suitable for prescribing; there is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP34858" outputclass="preTreatmentScreening">
    <title>Pre-treatment screening</title>
    <body>
      <section>
        <sectiondiv>
          <p>Exclude pregnancy before treatment.</p>
        </sectiondiv>
        <sectiondiv>
          <p>
Patients should have full blood count and renal and liver function tests before starting treatment.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP42910" outputclass="effectOnLaboratoryTests">
    <title>Effect on laboratory tests</title>
    <body>
      <section>
        <sectiondiv>
          <p>May suppress skin test reactions.</p>
        </sectiondiv>
        <sectiondiv>
          <p>
Post administration total plasma cortisol levels during 30-minute test for diagnosis of adrenocotical insufficiency might be misleading due to altered cortisol binding globulin levels in some special clinical situations including, patients on oral contraceptives, post-operative patients, critical illness, severe liver disease and nephrotic syndrome.
</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP72138" outputclass="professionSpecificInformation">
    <title>Profession specific information</title>
    <body>
      <section outputclass="dentalPractitionersFormulary">
        <title>Dental practitioners' formulary</title>
        <sectiondiv>
          <p outputclass="specificity">
  With
  <ph outputclass="route">oral</ph>
  use
  </p>
          <p>Azithromycin Capsules may be prescribed.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
  With
  <ph outputclass="route">oral</ph>
  use
  </p>
          <p>Azithromycin Tablets may be prescribed.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">
  With
  <ph outputclass="route">oral</ph>
  use
  </p>
          <p>
  Azithromycin Oral Suspension 200&#x202F;mg/5&#x202F;mL may be prescribed.
  </p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP65284" outputclass="exceptionsToLegalCategory">
    <title>Exceptions to legal category</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intranasal</ph> use</p>
          <p>Ephedrine nasal drops can be sold to the public provided no more than 180&#x202F;mg of ephedrine base (or salts) are supplied at one time, and pseudoephedrine salts are not supplied at the same time; for conditions that apply to supplies made at the request of a patient, see <i>Medicines, Ethics and Practice</i>, London, Pharmaceutical Press (always consult latest edition).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in adults</p>
          <p>For exceptions relating to ephedrine tablets see <i>Medicines, Ethics and Practice</i>, London, Pharmaceutical Press (always consult latest edition).</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP40761" outputclass="allergyAndCrossSensitivity">
    <title>Allergy and cross-sensitivity</title>
    <body>
      <section outputclass="allergyAndCrossSensitivityContraindications">
        <sectiondiv>
          <p>Contraindicated in sulfonamide hypersensitivity.</p>
        </sectiondiv>
      </section>
      <section outputclass="allergyAndCrossSensitivityCrossSensitivity">
        <sectiondiv>
          <p>Antiepileptic hypersensitivity syndrome theoretically associated with zonisamide. See under <xref format="dita" href="#PHP78230" type="bookmark">Epilepsy</xref> for more information.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP5143-medicinalForms" outputclass="medicinalForms">
    <title>Medicinal forms</title>
    <body>
      <section outputclass="licensingVariationStatement">
        <p>There can be variation in the licensing of different medicines containing the same drug.</p>
      </section>
      <p>Forms available from special-order manufacturers include: eye drops, solution for injection, irrigation, solution for infusion, oral solution, capsule, eye ointment, nebuliser liquid, infusion</p>
    </body>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76645" title="Modified-release tablet">Modified-release tablet</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76696" title="Oral solution">Oral solution</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76729" title="Solution for injection">Solution for injection</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76736" title="Infusion">Infusion</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76722" title="Nebuliser liquid">Nebuliser liquid</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76749" title="Eye drops">Eye drops</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76689" title="Eye ointment">Eye ointment</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76659" title="Spray">Spray</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76715" title="Irrigation solution">Irrigation solution</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76702" title="Intravesical solution">Intravesical solution</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP76667" title="Not applicable">Not applicable</xref>
      <xref format="dita" scope="local" type="medicinalForm" href="#PHP0000119" title="Products without form">Products without form</xref>
  </topic>
  <parents>
    <xref format="dita" scope="local" type="drugs" href="#drugs" title="Drugs">Drugs</xref>
  </parents>
</topic>
<topic id="PHP107558" outputclass="drug">
  <title>ST JOHN'S WORT</title>
  <topic id="PHP107570" outputclass="drugAction">
    <title>Drug action</title>
    <body>
      <section>
        <sectiondiv>
          <p>St John's wort is a herbal medicine included only for its potential to interact with drugs.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
</topic>
<topic id="PHP6461" outputclass="drug" rev="1.11">
  <title>ETHINYLESTRADIOL WITH ETONOGESTREL</title>
  <body>
    <data name="doi">doi:10.18578/BNF_778077044</data>
    <p outputclass="interactionsLinks"> List of individual interactants: <xref format="dita" href="bnf_int_783.xml">Ibuprofen</xref></p>
    <p outputclass="constituentDrugs">The properties listed below are those particular to the combination only. For the properties of the components please consider, <xref format="dita" href="PHP4479.xml">ethinylestradiol</xref>, <xref format="dita" href="PHP97243.xml">etonogestrel</xref>.</p>
    <data name="vtmid">38268001</data>
    <data name="classifications">
      <data name="classification">
        <data name="drugClassification">_322611837</data>
      </data>
    </data>
    <data name="primaryDomainOfEffect">
      <data name="domainOfEffect"> musculoskeletal system   </data>
    </data>
    <data name="secondaryDomainsOfEffect">
      <data name="domainOfEffect"> cardiovascular system  </data>
      <data name="domainOfEffect"> genito-urinary system  </data>
      <data name="domainOfEffect"> nervous system   </data>
    </data>
    <p outputclass="synonyms">
      <b>Hydroxyurea</b>
      <b>Ethinylestradiol</b>
      <b>Etonogestrel</b>
    </p>
  </body>
  <topic id="PHP42396" outputclass="drugAction" rev="1.39">
    <title>Drug action</title>
    <body>
      <section>
        <sectiondiv>
          <p>The glycopeptide antibiotic vancomycin has bactericidal activity against aerobic and anaerobic Gram-positive bacteria including multi-resistant staphylococci. However, there are reports of <ph outputclass="organism"><i>Staphylococcus aureus</i></ph> with reduced susceptibility to glycopeptides. There are increasing reports of glycopeptide-resistant enterococci. Penetration into cerebrospinal fluid is poor.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Vancomycin has a long duration of action and can therefore be given every 12 hours.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>An imidazole derivative which acts as a potent inhibitor of cortisol and aldosterone synthesis by inhibiting the activity of 17α-hydroxylase, 11-hydroxylation steps and at higher doses the cholesterol side-chain cleavage enzyme.</p>
          <p>It also inhibits the activity of adrenal C17-20 lyase enzymes resulting in androgen synthesis inhibition, and may have a direct effect on corticotropic tumour cells in patients with Cushing's disease.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47421" outputclass="indicationsAndDose" rev="1.53">
    <title>Indications and dose</title>
    <body>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Treatment of focal spasticity (including hand and wrist disability associated with stroke) (specialist use only)</p>
          <p outputclass="therapeuticIndication">Blepharospasm (specialist use only)</p>
          <p outputclass="therapeuticIndication">Hemifacial spasm (specialist use only)</p>
          <p outputclass="therapeuticIndication">Spasmodic torticollis (specialist use only)</p>
          <p outputclass="therapeuticIndication">Severe hyperhidrosis of the axillae (specialist use only)</p>
          <p outputclass="therapeuticIndication">Prophylaxis of headaches in adults with chronic migraine (specialist use only)</p>
          <p outputclass="therapeuticIndication">Temporary improvement of moderate to severe wrinkles between the eyebrows in adults under 65 years (specialist use only)</p>
          <p outputclass="therapeuticIndication">Ankle disability due to lower limb spasticity associated with stroke (specialist use only)</p>
          <p outputclass="therapeuticIndication">Management of bladder dysfunctions (specialist use only)</p>
          <p outputclass="therapeuticIndication">Temporary improvement of moderate to severe crow's feet (specialist use only)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By subcutaneous injection, or by intradermal injection, or by intramuscular injection</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>(consult product literature).</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in rheumatic disease and other musculoskeletal disorders</p>
          <p outputclass="therapeuticIndication">Mild to moderate pain including dysmenorrhoea</p>
          <p outputclass="therapeuticIndication">Postoperative analgesia</p>
          <p outputclass="therapeuticIndication">Migraine</p>
          <p outputclass="therapeuticIndication">Dental pain</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 300–400 mg 3–4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200–400 mg 3 times a day, may be adequate.</p>
          </li>
        </ul>
        <p outputclass="routesOfAdministration">By mouth using modified-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>1.6 g once daily, dose to be taken in the early evening, increased if necessary to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">
            <ph outputclass="organism">
              <i>
                <i>Clostridium difficile</i>
              </i>
            </ph> infection</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>125 mg 4 times a day for 10–14 days, dose may be increased if infection fails to respond or is life-threatening, increased if necessary up to 500 mg 4 times a day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Mild to moderate pain</p>
          <p outputclass="therapeuticIndication">Pain and inflammation of soft-tissue injuries</p>
          <p outputclass="therapeuticIndication">Pyrexia with discomfort</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">Initially by mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3–5 months</p>
            <p>50 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 6–11 months</p>
            <p>50 mg 3–4 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 1–3 years</p>
            <p>100 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 4–6 years</p>
            <p>150 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 7–9 years</p>
            <p>200 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 10–11 years</p>
            <p>300 mg 3 times a day, maximum daily dose to be given in 3–4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</p>
          </li>
          <li outputclass="patientGroup child">
            <p>Child 12–17 years</p>
            <p>Initially 300–400 mg 3–4 times a day; (by mouth using immediate-release medicines) increased if necessary up to 600 mg 4 times a day; (by mouth) maintenance 200–400 mg 3 times a day, may be adequate.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using modified-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 12–17 years</p>
            <p>1.6 g once daily, dose preferably taken in the early evening, increased to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3 months–17 years</p>
            <p>30–40 mg/kg daily in 3–4 divided doses; maximum 2.4 g per day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain and inflammation in systemic juvenile idiopathic arthritis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 3 months–17 years</p>
            <p>Up to 60 mg/kg daily in 4–6 divided doses; maximum 2.4 g per day.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Post-immunisation pyrexia in infants (on doctor’s advice only)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth using immediate-release medicines</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup child">
            <p>Child 2–3 months</p>
            <p>50 mg for 1 dose, followed by 50 mg after 6 hours if required.</p>
          </li>
          <li outputclass="patientGroup neonate">
            <p>Neonate</p>
            <p>50 mg for 1 dose, followed by 50 mg after 6 hours if required.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Pain relief in musculoskeletal conditions</p>
          <p outputclass="therapeuticIndication">Treatment in knee or hand osteoarthritis (adjunct)</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">To the skin</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
          <li outputclass="patientGroup adult female">
            <p>Adult (Female patients)</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
          <li outputclass="patientGroup adult male">
            <p>Adult (Male patients)</p>
            <p>Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult 18–69 years</p>
            <p>Initially 5–10 mg once daily, then increased if necessary to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
          <li outputclass="patientGroup adult asian">
            <p>Adult (patients of Asian origin)</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
          <li outputclass="patientGroup adult eastAsian">
            <p>Adult (patients of East Asian origin)</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia), mixed dyslipidaemia (type IIb), or homozygous familial hypercholesterolaemia in patients who have not responded adequately to diet and other appropriate measures and who have risk factors for myopathy or rhabdomyolysis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily, dose to be increased at intervals of at least 4 weeks.</p>
          </li>
        </ul>
      </section>
      <section outputclass="indicationAndDoseGroup">
        <sectiondiv outputclass="therapeuticIndications">
          <p outputclass="therapeuticIndication">Prevention of cardiovascular events in patients at high risk of a first cardiovascular event and with risk factors for myopathy or rhabdomyolysis</p>
        </sectiondiv>
        <p outputclass="routesOfAdministration">By mouth</p>
        <ul outputclass="patientGroups">
          <li outputclass="patientGroup adult">
            <p>Adult</p>
            <p>Initially 5 mg once daily, then increased if necessary up to 20 mg once daily.</p>
          </li>
        </ul>
      </section>
      <section outputclass="pharmacokinetics">
        <title>Pharmacokinetics</title>
        <p>Vancomycin should <b>not</b> be given by mouth for systemic infections because it is not absorbed significantly.</p>
      </section>
      <section outputclass="doseEquivalence">
        <title>Dose equivalence and conversion</title>
        <p>480 mg of co-trimoxazole consists of sulfamethoxazole 400 mg and trimethoprim 80 mg. </p>
      </section>
      <sectiondiv>
        <p>Initially 5 mg once daily with concomitant fibrate increased if necessary to max. 20 mg daily. For dose adjustments with concomitant atazanavir, clopidogrel, darunavir, dronedarone, eltrombopag, ezetimibe, itraconazole, lopinavir, or tipranavir, consult product literature.</p>
      </sectiondiv>
    </body>
  </topic>
  <topic id="PHP87039" outputclass="directionsForAdministration" rev="1.19">
    <title>Directions for administration</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="title">Changing method of contraception to vaginal ring</p>
          <p>Insert ring at the latest on the day after the usual tablet-free, patch-free, or inactive-tablet interval. If previous contraceptive used correctly, or pregnancy can reasonably be excluded, can switch to ring on any day of cycle.</p>
          <sectiondiv>
            <p outputclass="title">Changing from progestogen-only method</p>
            <p>From an implant or intra-uterine progestogen-only device, insert ring on the day implant or intra-uterine progestogen-only device removed; from an injection, insert ring when next injection due; from oral preparation, first ring may be inserted on any day after stopping pill. For all methods additional precautions (barrier methods) should be used concurrently for first 7 days.</p>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP73139" outputclass="importantSafetyInformation" rev="1.17">
    <title>Important safety information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p outputclass="title">MHRA/CHM advice (June 2015) Intra-uterine contraception: uterine perforation—updated information on risk factors</p>
          <p>Uterine perforation most often occurs during insertion, but might not be detected until sometime later. The risk of uterine perforation is increased when the device is inserted up to 36 weeks postpartum or in patients who are breastfeeding. Before inserting an intra-uterine contraceptive device, inform patients that perforation occurs in approximately 1 in every 1000 insertions and signs and symptoms include:</p>
          <ul>
            <li>severe pelvic pain after insertion (worse than period cramps);</li>
            <li>pain or increased bleeding after insertion which continues for more than a few weeks;</li>
            <li>sudden changes in periods;</li>
            <li>pain during intercourse;</li>
            <li>unable to feel the threads.</li>
          </ul>
          <p>Patients should be informed on how to check their threads and to arrange a check-up if threads cannot be felt, especially if they also have significant pain. Partial perforation may occur even if the threads can be seen; consider this if there is severe pain following insertion and perform an ultrasound.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47320" outputclass="unlicensedUse" rev="1.21">
    <title>Unlicensed use</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Orphan licence for the injection for closure of ductus arteriosus in premature neonates less than 34 weeks corrected gestational age.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Not licensed for use in children under 3 months or body-weight under 5 kg.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Not licensed for typhoid fever, Lyme disease, chronic <ph outputclass="organism"><i>Pseudomonas aeruginosa</i></ph> infection in cystic fibrosis, or prophylaxis of group A streptococcal infection.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in adults</p>
          <p>Oral azithromycin not licensed for trachoma which results from chronic infection with <ph outputclass="organism"><i>Chlamydia trachomatis</i></ph>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use in adults</p>
          <p>Not licensed for uncomplicated gonorrhoea, mild or moderate typhoid due to multiple-antibacterial-resistant organisms, Lyme disease, or prophylaxis of group A streptococcal infection.</p>
          <p>Not licensed for community-acquired pneumonia (high severity) when oral treatment continues for more than 3 days.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute anaphylaxis</ph> in children</p>
          <p>Auto-injector delivering 150-microgram dose of adrenaline not licensed for use in children body-weight under 15 kg.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use for <ph outputclass="indication">acute hypotension</ph> in children</p>
          <p>Adrenaline 1 in 1000 (1 mg/mL) solution is not licensed for intravenous administration.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP54740" outputclass="contraindications" rev="1.8">
    <title>Contra-indications</title>
    <body>
      <section outputclass="contraindications">
        <p>
          <ph outputclass="contraindication">Intestinal obstruction</ph>
        </p>
        <sectiondiv outputclass="additionalContraindications">
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intravenous use</p>
            <p>
              <ph outputclass="contraindication">active bleeding (especially intracranial or gastro-intestinal)</ph> (in neonates); <ph outputclass="contraindication">coagulation defects</ph> (in neonates); <ph outputclass="contraindication">known or suspected necrotising enterocolitis</ph> (in neonates); <ph outputclass="contraindication">life-threatening infection</ph> (in neonates); <ph outputclass="contraindication">marked unconjugated hyperbilirubinaemia</ph> (in neonates); <ph outputclass="contraindication">pulmonary hypertension</ph> (in neonates); <ph outputclass="contraindication">thrombocytopenia</ph> (in neonates)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="contraindication">active gastro-intestinal bleeding</ph> (in children); <ph outputclass="contraindication">active gastro-intestinal ulceration</ph> (in children); <ph outputclass="contraindication">history of gastro-intestinal bleeding related to previous NSAID therapy</ph> (in children); <ph outputclass="contraindication">history of gastro-intestinal perforation related to previous NSAID therapy</ph> (in children); <ph outputclass="contraindication">history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)</ph> (in children); <ph outputclass="contraindication">history of recurrent gastro-intestinal ulceration (two or more distinct episodes)</ph> (in children); <ph outputclass="contraindication">severe heart failure</ph> (in children)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With systemic use</p>
            <p>
              <ph outputclass="contraindication">active gastro-intestinal bleeding</ph> (in adults); <ph outputclass="contraindication">active gastro-intestinal ulceration</ph> (in adults); <ph outputclass="contraindication">history of gastro-intestinal bleeding related to previous NSAID therapy</ph> (in adults); <ph outputclass="contraindication">history of gastro-intestinal perforation related to previous NSAID therapy</ph> (in adults); <ph outputclass="contraindication">history of recurrent gastro-intestinal haemorrhage (two or more distinct episodes)</ph> (in adults); <ph outputclass="contraindication">history of recurrent gastro-intestinal ulceration (two or more distinct episodes)</ph> (in adults); <ph outputclass="contraindication">severe heart failure</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intra-uterine use</p>
            <p>
              <ph outputclass="contraindication">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration</ph>; <ph outputclass="contraindication">acute cervicitis</ph>; <ph outputclass="contraindication">acute vaginitis</ph>; <ph outputclass="contraindication">distorted uterine cavity</ph>; <ph outputclass="contraindication">established immunosuppression</ph>; <ph outputclass="contraindication">genital malignancy</ph>; <ph outputclass="contraindication">history of breast cancer but can be considered for a woman in long-term remission who has menorrhagia and requires effective contraception</ph>; <ph outputclass="contraindication">infected abortion during the previous three months</ph>; <ph outputclass="contraindication">marked immunosuppression</ph>; <ph outputclass="contraindication">not suitable for emergency contraception</ph>; <ph outputclass="contraindication">pelvic inflammatory disease</ph>; <ph outputclass="contraindication">postpartum endometritis</ph>; <ph outputclass="contraindication">recent sexually transmitted infection (if not fully investigated and treated)</ph>; <ph outputclass="contraindication">severe anaemia</ph>; <ph outputclass="contraindication">small uterine cavity</ph>; <ph outputclass="contraindication">unexplained uterine bleeding</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="contraindication">
                <xref format="dita" href="PHP78608.xml" type="bookmark">Acute porphyrias</xref>
              </ph>
            </p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for contraception</ph>
              <ph outputclass="contraindication">history of breast cancer but can be used after 5 years if no evidence of disease and non-hormonal contraceptive methods unacceptable</ph>; <ph outputclass="contraindication">severe arterial disease</ph>; <ph outputclass="contraindication">undiagnosed vaginal bleeding</ph></p>
          </sectiondiv>
      </section>
      <section outputclass="importantAdvice">
        <title>Contra-indications, further information</title>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">regional administration</ph></p>
          <p outputclass="title">Injection site</p>
          <p>Local anaesthetics should not be injected into inflamed or infected tissues nor should they be applied to damaged skin. Increased absorption into the blood increases the possibility of systemic side-effects, and the local anaesthetic effect may also be reduced by altered local pH.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47574" outputclass="cautions" rev="1.66">
    <title>Cautions</title>
    <body>
      <section outputclass="cautions">
        <p>
          <ph outputclass="caution">
            <xref format="dita" href="PHP78608.xml" type="bookmark">Acute porphyrias</xref>
          </ph>; <ph outputclass="caution">diarrhoea</ph>; <ph outputclass="caution">extreme caution in blood disorders (avoid if severe)</ph>; <ph outputclass="caution">peptic ulceration</ph>; <ph outputclass="caution">photosensitivity—psoriasis lesions aggravated by UV radiation (skin ulceration reported)</ph>; <ph outputclass="caution">risk of accumulation in pleural effusion or ascites— drain before treatment</ph>; <ph outputclass="caution">ulcerative colitis</ph>; <ph outputclass="caution">ulcerative stomatitis</ph></p>
        <sectiondiv outputclass="additionalCautions">
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With intravenous use</p>
            <p>
              <ph outputclass="caution">may mask symptoms of infection</ph> (in neonates)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With oral use</p>
            <p>
              <ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph> (in children); <ph outputclass="caution">cerebrovascular disease</ph> (in children); <ph outputclass="caution">coagulation defects</ph> (in children); <ph outputclass="caution">connective-tissue disorders</ph> (in children); <ph outputclass="caution">Crohn’s disease (may be exacerbated)</ph> (in children); <ph outputclass="caution">heart failure</ph> (in children); <ph outputclass="caution">ischaemic heart disease</ph> (in children); <ph outputclass="caution">peripheral arterial disease</ph> (in children); <ph outputclass="caution">risk factors for cardiovascular events</ph> (in children); <ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph> (in children); <ph outputclass="caution">uncontrolled hypertension</ph> (in children)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With systemic use</p>
            <p>
              <ph outputclass="caution">allergic disorders</ph> (in adults); <ph outputclass="caution">cardiac impairment (NSAIDs may impair renal function)</ph> (in adults); <ph outputclass="caution">cerebrovascular disease</ph> (in adults); <ph outputclass="caution">coagulation defects</ph> (in adults); <ph outputclass="caution">connective-tissue disorders</ph> (in adults); <ph outputclass="caution">Crohn’s disease (may be exacerbated)</ph> (in adults); <ph outputclass="caution">elderly (risk of serious side-effects and fatalities)</ph> (in adults); <ph outputclass="caution">heart failure</ph> (in adults); <ph outputclass="caution">ischaemic heart disease</ph> (in adults); <ph outputclass="caution">peripheral arterial disease</ph> (in adults); <ph outputclass="caution">risk factors for cardiovascular events</ph> (in adults); <ph outputclass="caution">ulcerative colitis (may be exacerbated)</ph> (in adults); <ph outputclass="caution">uncontrolled hypertension</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithRoutes">
            <p outputclass="title">With topical use</p>
            <p>
              <ph outputclass="caution">avoid contact with eyes</ph> (in adults); <ph outputclass="caution">avoid contact with inflamed or broken skin</ph> (in adults); <ph outputclass="caution">avoid contact with mucous membranes</ph> (in adults); <ph outputclass="caution">not for use with occlusive dressings</ph> (in adults); <ph outputclass="caution">topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported)</ph> (in adults)</p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for contraception</ph>
              <ph outputclass="caution">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice</ph>; <ph outputclass="caution">arterial disease</ph>; <ph outputclass="caution">functional ovarian cysts</ph>; <ph outputclass="caution">history of jaundice in pregnancy</ph>; <ph outputclass="caution">malabsorption syndromes</ph>; <ph outputclass="caution">past ectopic pregnancy</ph>; <ph outputclass="caution">sex-steroid dependent cancer</ph>; <ph outputclass="caution">systemic lupus erythematosus with positive (or unknown) antiphospholipid antibodies</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="cautionsOrContraindicationsWithIndications">
            <p outputclass="title">When used for emergency contraception</p>
            <p>
              <ph outputclass="routesAndIndications">with <ph outputclass="route">oral</ph> use for emergency contraception</ph>
              <ph outputclass="caution">active trophoblastic disease (until return to normal of urine- and plasma-gonadotrophin concentration)—seek specialist advice</ph>; <ph outputclass="caution">past ectopic pregnancy</ph>; <ph outputclass="caution">severe malabsorption syndromes</ph></p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="importantAdvice">
        <title>Cautions, further information</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p outputclass="title">Use as a contraceptive in co-morbidities</p>
          <p>The product literature advises caution in patients with history of thromboembolism, hypertension, diabetes meillitus and migraine; evidence for caution in these conditions is unsatisfactory.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">High-dose ibuprofen</p>
          <p>A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose ibuprofen (≥ 2.4 g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II-III), and uncontrolled hypertension.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Risk of infection with intra-uterine devices</p>
          <p>The main excess risk of infection occurs in the first 20 days after insertion and is believed to be related to existing carriage of a sexually transmitted infection. Women are considered to be at a higher risk of sexually transmitted infections if:</p>
          <ul>
            <li>they are under 25 years old <i>or</i></li>
            <li>they are over 25 years old <i>and</i></li>
            <li>have a new partner <i>or</i></li>
            <li>have had more than one partner in the past year <i>or</i></li>
            <li>their regular partner has other partners.</li>
          </ul>
          <p>In these women, pre-insertion screening (for chlamydia and, depending on sexual history and local prevalence of disease, <ph outputclass="organism"><i>Neisseria gonorrhoeae</i></ph>) should be performed. If results are unavailable at the time of fitting an intrauterine device for emergency contraception, appropriate prophylactic antibacterial cover should be given. The woman should be advised to attend <i>as an emergency</i> if she experiences sustained pain during the next 20 days.</p>
          <p>An intra-uterine device should not be removed in mid-cycle unless an additional contraceptive was used for the previous 7 days. If removal is essential post-coital contraception should be considered.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47409" outputclass="interactions" rev="1.10">
    <title>Interactions</title>
    <body>
      <section outputclass="general">
        <sectiondiv>
          <p>Appendix 1 (NSAIDs).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Interactions do not generally apply to topical NSAIDs.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47342" outputclass="sideEffects" rev="1.49">
    <title>Side-effects</title>
    <body>
      <section outputclass="generalSideEffects">
        <title>General side-effects:</title>
        <sectiondiv outputclass="frequencies">
          <sectiondiv outputclass="commonOrVeryCommon">
            <p outputclass="title">Common or very common</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Depression (sometimes severe)</ph>; <ph outputclass="sideEffect">headache</ph>; <ph outputclass="sideEffect">nausea</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="uncommon">
            <p outputclass="title">Uncommon</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Anorexia</ph>; <ph outputclass="sideEffect">antibiotic-associated colitis</ph>; <ph outputclass="sideEffect">anxiety</ph>; <ph outputclass="sideEffect">blood disorders</ph>; <ph outputclass="sideEffect">convulsions</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">dysuria</ph>; <ph outputclass="sideEffect">glycosuria</ph>; <ph outputclass="sideEffect">hyperkalaemia</ph>; <ph outputclass="sideEffect">hypoaesthesia</ph>; <ph outputclass="sideEffect">influenza-like symptoms</ph>; <ph outputclass="sideEffect">memory impairment</ph>; <ph outputclass="sideEffect">paraesthesia</ph>; <ph outputclass="sideEffect">peripheral oedema</ph>; <ph outputclass="sideEffect">polymenorrhoea</ph>; <ph outputclass="sideEffect">polyuria</ph>; <ph outputclass="sideEffect">sleep disturbances</ph>; <ph outputclass="sideEffect">taste disturbances</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="rare">
            <p outputclass="title">Rare</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Blood pressure changes</ph>; <ph outputclass="sideEffect">constipation</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="veryRare">
            <p outputclass="title">Very rare</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Anorexia</ph>; <ph outputclass="sideEffect">antibiotic-associated colitis</ph>; <ph outputclass="sideEffect">arthralgia</ph>; <ph outputclass="sideEffect">aseptic meningitis</ph>; <ph outputclass="sideEffect">ataxia</ph>; <ph outputclass="sideEffect">blood disorders</ph>; <ph outputclass="sideEffect">convulsions</ph>; <ph outputclass="sideEffect">cough</ph>; <ph outputclass="sideEffect">depression</ph>; <ph outputclass="sideEffect">eosinophilia</ph>; <ph outputclass="sideEffect">glossitis</ph>; <ph outputclass="sideEffect">hallucinations</ph>; <ph outputclass="sideEffect">hepatic necrosis</ph>; <ph outputclass="sideEffect">hypoglycaemia</ph>; <ph outputclass="sideEffect">hyponatraemia</ph>; <ph outputclass="sideEffect">interstitial nephritis</ph>; <ph outputclass="sideEffect">jaundice</ph>; <ph outputclass="sideEffect">leucopenia</ph>; <ph outputclass="sideEffect">liver damage</ph>; <ph outputclass="sideEffect">megaloblastic anaemia</ph>; <ph outputclass="sideEffect">myalgia</ph>; <ph outputclass="sideEffect">myocarditis</ph>; <ph outputclass="sideEffect">pancreatitis</ph>; <ph outputclass="sideEffect">peripheral neuropathy</ph>; <ph outputclass="sideEffect">photosensitivity</ph>; <ph outputclass="sideEffect">pulmonary infiltrates</ph>; <ph outputclass="sideEffect">renal disorders</ph>; <ph outputclass="sideEffect">shortness of breath</ph>; <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph>; <ph outputclass="sideEffect">stomatitis</ph>; <ph outputclass="sideEffect">systemic lupus erythematosus</ph>; <ph outputclass="sideEffect">thrombocytopenia</ph>; <ph outputclass="sideEffect">tinnitus</ph>; <ph outputclass="sideEffect">toxic epidermal necrolysis</ph>; <ph outputclass="sideEffect">uveitis</ph>; <ph outputclass="sideEffect">vasculitis</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
          </sectiondiv>
          <sectiondiv outputclass="notKnown">
            <p outputclass="title">Frequency not known</p>
            <p outputclass="sideEffects">
              <ph outputclass="sideEffect">Vomiting</ph>
            </p>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="specificSideEffects">
        <sectiondiv outputclass="frequencies">
          <sectiondiv outputclass="commonOrVeryCommon">
            <p outputclass="title">Common or very common</p>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">nausea</ph>; <ph outputclass="sideEffect">dizziness</ph>; <ph outputclass="sideEffect">vomiting</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">abdominal distension</ph>; <ph outputclass="sideEffect">alopecia</ph>; <ph outputclass="sideEffect">anaemia</ph>; <ph outputclass="sideEffect">anxiety</ph>; <ph outputclass="sideEffect">bronchitis</ph>; <ph outputclass="sideEffect">cellulitis</ph>; <ph outputclass="sideEffect">cough</ph>; <ph outputclass="sideEffect">diarrhoea</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">epistaxis</ph>; <ph outputclass="sideEffect">fever</ph>; <ph outputclass="sideEffect">gastritis</ph>; <ph outputclass="sideEffect">gastro-oesophageal reflux</ph>; <ph outputclass="sideEffect">haemorrhoids</ph>; <ph outputclass="sideEffect">headache</ph>; <ph outputclass="sideEffect">influenza-like symptoms</ph>; <ph outputclass="sideEffect">insomnia</ph>; <ph outputclass="sideEffect">limb pain</ph>; <ph outputclass="sideEffect">night sweats</ph>; <ph outputclass="sideEffect">oedema</ph>; <ph outputclass="sideEffect">painful red eyes</ph>; <ph outputclass="sideEffect">paraesthesia</ph>; <ph outputclass="sideEffect">photophobia</ph>; <ph outputclass="sideEffect">retinal haemorrhage</ph>; <ph outputclass="sideEffect">tremor</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">bronchopulmonary dysplasia</ph> (in neonates); <ph outputclass="sideEffect">fluid retention</ph> (in neonates); <ph outputclass="sideEffect">haematuria</ph> (in neonates); <ph outputclass="sideEffect">hyponatraemia</ph> (in neonates); <ph outputclass="sideEffect">intestinal perforation</ph> (in neonates); <ph outputclass="sideEffect">intraventricular haemorrhage</ph> (in neonates); <ph outputclass="sideEffect">ischaemic brain injury</ph> (in neonates); <ph outputclass="sideEffect">neutropenia</ph> (in neonates); <ph outputclass="sideEffect">oliguria</ph> (in neonates); <ph outputclass="sideEffect">pulmonary haemorrhage</ph> (in neonates); <ph outputclass="sideEffect">thrombocytopenia</ph> (in neonates)</p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="uncommon">
            <p outputclass="title">Uncommon</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">gastrointestinal haemorrhage</ph> (in neonates)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">chest pain</ph>; <ph outputclass="sideEffect">drowsiness</ph>; <ph outputclass="sideEffect">dry mouth</ph>; <ph outputclass="sideEffect">epistaxis</ph>; <ph outputclass="sideEffect">fatigue</ph>; <ph outputclass="sideEffect">hypertension</ph>; <ph outputclass="sideEffect">hypoaesthesia</ph>; <ph outputclass="sideEffect">hypotension</ph>; <ph outputclass="sideEffect">painful red eyes</ph>; <ph outputclass="sideEffect">palpitation</ph>; <ph outputclass="sideEffect">tachycardia</ph>; <ph outputclass="sideEffect">tinnitus</ph>; <ph outputclass="sideEffect">vertigo</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">gynaecomastia</ph>; <ph outputclass="sideEffect">haematuria</ph>; <ph outputclass="sideEffect">penile haemorrhage</ph>; <ph outputclass="sideEffect">priapism</ph></p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="rare">
            <p outputclass="title">Rare</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">alveolitis</ph> (in children); <ph outputclass="sideEffect">aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)</ph> (in children); <ph outputclass="sideEffect">hepatic damage</ph> (in children); <ph outputclass="sideEffect">interstitial fibrosis associated with NSAIDs can lead to renal failure</ph> (in children); <ph outputclass="sideEffect">pancreatitis</ph> (in children); <ph outputclass="sideEffect">papillary necrosis associated with NSAIDs can lead to renal failure</ph> (in children); <ph outputclass="sideEffect">pulmonary eosinophilia</ph> (in children); <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph> (in children); <ph outputclass="sideEffect">toxic epidermal necrolysis</ph> (in children); <ph outputclass="sideEffect">visual disturbances</ph> (in children)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With systemic use</p>
              <p>
                <ph outputclass="sideEffect">alveolitis</ph> (in adults); <ph outputclass="sideEffect">aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible)</ph> (in adults); <ph outputclass="sideEffect">hepatic damage</ph> (in adults); <ph outputclass="sideEffect">interstitial fibrosis associated with NSAIDs can lead to renal failure</ph> (in adults); <ph outputclass="sideEffect">pancreatitis</ph> (in adults); <ph outputclass="sideEffect">papillary necrosis associated with NSAIDs can lead to renal failure</ph> (in adults); <ph outputclass="sideEffect">pulmonary eosinophilia</ph> (in adults); <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph> (in adults); <ph outputclass="sideEffect">toxic epidermal necrolysis</ph> (in adults); <ph outputclass="sideEffect">visual disturbances</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">atrial fibrillation</ph>; <ph outputclass="sideEffect">cerebrovascular accident</ph>; <ph outputclass="sideEffect">facial oedema</ph>; <ph outputclass="sideEffect">hypersensitivity reactions</ph>; <ph outputclass="sideEffect">priapism</ph>; <ph outputclass="sideEffect">rash</ph>; <ph outputclass="sideEffect">Stevens-Johnson syndrome</ph>; <ph outputclass="sideEffect">syncope</ph></p>
            </sectiondiv>
          </sectiondiv
          <sectiondiv outputclass="veryRare">
            <p outputclass="title">Very rare</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">pyrexia</ph>
              </p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for blepharospasm</p>
              <p>
                <ph outputclass="sideEffect">angle-closure glaucoma</ph>; <ph outputclass="sideEffect">corneal epithelial defect</ph>; <ph outputclass="sideEffect">corneal perforation</ph>; <ph outputclass="sideEffect">corneal ulceration</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for hemifacial spasm</p>
              <p>
                <ph outputclass="sideEffect">angle-closure glaucoma</ph>; <ph outputclass="sideEffect">corneal epithelial defect</ph>; <ph outputclass="sideEffect">corneal perforation</ph>; <ph outputclass="sideEffect">corneal ulceration</ph></p>
            </sectiondiv>
          </sectiondiv>
          <sectiondiv outputclass="notKnown">
            <p outputclass="title">Frequency not known</p>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With intravenous use</p>
              <p>
                <ph outputclass="sideEffect">hypoxaemia</ph> (in neonates)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With oral use</p>
              <p>
                <ph outputclass="sideEffect">angioedema</ph> (in children); <ph outputclass="sideEffect">blood disorders</ph> (in children); <ph outputclass="sideEffect">bronchospasm</ph> (in children); <ph outputclass="sideEffect">colitis (induction of or exacerbation of)</ph> (in children); <ph outputclass="sideEffect">Crohn’s disease (induction of or exacerbation of)</ph> (in children); <ph outputclass="sideEffect">depression</ph> (in children); <ph outputclass="sideEffect">diarrhoea</ph> (in children); <ph outputclass="sideEffect">dizziness</ph> (in children); <ph outputclass="sideEffect">drowsiness</ph> (in children); <ph outputclass="sideEffect">fluid retention (rarely precipitating congestive heart failure)</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal bleeding</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal discomfort</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal disturbances</ph> (in children); <ph outputclass="sideEffect">gastro-intestinal ulceration</ph> (in children); <ph outputclass="sideEffect">haematuria</ph> (in children); <ph outputclass="sideEffect">headache</ph> (in children); <ph outputclass="sideEffect">hearing disturbances</ph> (in children); <ph outputclass="sideEffect">hypersensitivity reactions</ph> (in children); <ph outputclass="sideEffect">insomnia</ph> (in children); <ph outputclass="sideEffect">nausea</ph> (in children); <ph outputclass="sideEffect">nervousness</ph> (in children); <ph outputclass="sideEffect">photosensitivity</ph> (in children); <ph outputclass="sideEffect">raised blood pressure</ph> (in children); <ph outputclass="sideEffect">rashes</ph> (in children); <ph outputclass="sideEffect">renal failure (especially in patients with pre-existing renal impairment)</ph> (in children); <ph outputclass="sideEffect">tinnitus</ph> (in children); <ph outputclass="sideEffect">vertigo</ph> (in children)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With systemic use</p>
              <p>
                <ph outputclass="sideEffect">angioedema</ph> (in adults); <ph outputclass="sideEffect">blood disorders</ph> (in adults); <ph outputclass="sideEffect">bronchospasm</ph> (in adults); <ph outputclass="sideEffect">colitis (induction of or exacerbation of)</ph> (in adults); <ph outputclass="sideEffect">Crohn’s disease (induction of or exacerbation of)</ph> (in adults); <ph outputclass="sideEffect">depression</ph> (in adults); <ph outputclass="sideEffect">diarrhoea</ph> (in adults); <ph outputclass="sideEffect">dizziness</ph> (in adults); <ph outputclass="sideEffect">drowsiness</ph> (in adults); <ph outputclass="sideEffect">fluid retention (rarely precipitating congestive heart failure)</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal bleeding</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal discomfort</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal disturbances</ph> (in adults); <ph outputclass="sideEffect">gastro-intestinal ulceration</ph> (in adults); <ph outputclass="sideEffect">haematuria</ph> (in adults); <ph outputclass="sideEffect">headache</ph> (in adults); <ph outputclass="sideEffect">hearing disturbances</ph> (in adults); <ph outputclass="sideEffect">hypersensitivity reactions</ph> (in adults); <ph outputclass="sideEffect">insomnia</ph> (in adults); <ph outputclass="sideEffect">nausea</ph> (in adults); <ph outputclass="sideEffect">nervousness</ph> (in adults); <ph outputclass="sideEffect">photosensitivity</ph> (in adults); <ph outputclass="sideEffect">raised blood pressure</ph> (in adults); <ph outputclass="sideEffect">rashes</ph> (in adults); <ph outputclass="sideEffect">renal failure (especially in patients with pre-existing renal impairment)</ph> (in adults); <ph outputclass="sideEffect">tinnitus</ph> (in adults); <ph outputclass="sideEffect">vertigo</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithRoutes">
              <p outputclass="title">With topical use</p>
              <p>
                <ph outputclass="sideEffect">photosensitivity</ph> (in adults); <ph outputclass="sideEffect">rash (discontinue use if develops)</ph> (in adults)</p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for erectile dysfunction</p>
              <p>
                <ph outputclass="sideEffect">arrhythmia</ph>; <ph outputclass="sideEffect">myocardial infarction</ph>; <ph outputclass="sideEffect">seizures</ph>; <ph outputclass="sideEffect">unstable angina</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for pulmonary arterial hypertension</p>
              <p>
                <ph outputclass="sideEffect">rash</ph>; <ph outputclass="sideEffect">retinal vascular occlusion</ph></p>
            </sectiondiv>
            <sectiondiv outputclass="sideEffectsWithIndications">
              <p outputclass="title">When used for uncomplicated premature labour</p>
              <p>
                <ph outputclass="routesAndIndications">with <ph outputclass="route">intravenous</ph> use for uncomplicated premature labour</ph>
                <ph outputclass="sideEffect">bronchospasm</ph> (in adults); <ph outputclass="sideEffect">muscle tension</ph> (in adults); <ph outputclass="sideEffect">pulmonary oedema</ph> (in adults); <ph outputclass="sideEffect">vomiting</ph> (in adults)</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
      </section>
      <section outputclass="sideEffectsAdvice">
        <title>Side-effects, further information</title>
        <sectiondiv>
          <p outputclass="title">Serious side-effects</p>
          <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="PHP78612.xml" type="bookmark">Non-steroidal anti-inflammatory drugs</xref>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).</p>
        </sectiondiv>
      </section>
      <section outputclass="sideEffectsOverdosageInformation">
        <title>Overdose</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>, in particular, Convulsions.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in children</p>
          <p>Mefenamic acid has important consequences in overdosage because it can cause convulsions, which if prolonged or recurrent, require treatment with intravenous lorazepam or diazepam.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>, in particular, Convulsions.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Overdosage with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. <xref format="dita" href="PHP182.xml" type="drug">Charcoal, activated</xref> followed by symptomatic measures are indicated if more than 100 mg/kg has been ingested within the preceding hour.</p>
          <p>For details on the management of poisoning, see <xref format="dita" href="PHP78558.xml" type="bookmark">Emergency treatment of poisoning</xref>.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP40380" outputclass="importantSafetyInformation" rev="1.8">
    <title>Important safety information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="title">Restrictions on the use of co-trimoxazole</p>
          <p>Co-trimoxazole is the drug of choice in the prophylaxis and treatment of <ph outputclass="organism"><i>Pneumocystis jirovecii</i></ph> (<ph outputclass="organism"><i>Pneumocystis carinii</i></ph>) pneumonia; it is also indicated for nocardiasis, <ph outputclass="organism"><i>Stenotrophomonas maltophilia</i></ph> infection [unlicensed indication], and toxoplasmosis. It should only be considered for use in acute exacerbations of chronic bronchitis and infections of the urinary tract when there is bacteriological evidence of sensitivity to co-trimoxazole and good reason to prefer this combination to a single antibacterial; similarly it should only be used in acute otitis media in children when there is good reason to prefer it. Co-trimoxazole is also used for the treatment of infections caused by <ph outputclass="organism"><i>Burkholderia cepacia</i></ph> in cystic fibrosis [unlicensed indication].</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47602" outputclass="allergyAndCrossSensitivity" rev="1.12">
    <title>Allergy and cross-sensitivity</title>
    <body>
      <section outputclass="allergyAndCrossSensitivityContraindications">
        <sectiondiv>
          <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID—which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
        </sectiondiv>
      </section>
      <section outputclass="allergyAndCrossSensitivityCrossSensitivity">
        <sectiondiv>
          <p>Caution if teicoplanin sensitivity.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47531" outputclass="conceptionAndContraception">
    <title>Conception and contraception</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Caution—long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
        </sectiondiv>
          <sectiondiv>
            <p>Exclude pregnancy before treatment with cytotoxic drugs.</p>
            <p>Contraceptive advice should be given before cytotoxic therapy begins; manufacturer advises effective contraception before and during treatment.</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="specificity">When used for <ph outputclass="indication">Chronic myeloid leaukaemia</ph> or <ph outputclass="indication">Cancer of the cervix</ph></p>
            <p>Regimens that do not contain an alkylating drug or procarbazine may have less effect on fertility, but those with an alkylating drug or procarbazine carry the risk of causing permanent male sterility (there is no effect on potency). Pretreatment counselling and consideration of sperm storage may be appropriate. Women are less severely affected, though the span of reproductive life may be shortened by the onset of a premature menopause. No increase in fetal abnormalities or abortion rate has been recorded in patients who remain fertile after cytotoxic chemotherapy.</p>
          </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47397" outputclass="pregnancy">
    <title>Pregnancy</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">vaginal</ph> use</p>
          <p>Pregnant women need a longer duration of treatment, usually about 7 days, to clear the infection. Oral antifungal treatment should be avoided during pregnancy.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Avoid unless the potential benefit outweighs the risk.</p>
          <p>Avoid during the third trimester (risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Patient packs for topical preparations carry a warning to avoid during pregnancy.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Arrhythmias</ph> or <ph outputclass="indication">Prevention of seizures in pre-eclampsia</ph> or <ph outputclass="indication">Treatment of seizures and prevention of seizure recurrence in eclampsia</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in adults</p>
          <p>Not known to be harmful for short-term intravenous administration in eclampsia, but excessive doses in third trimester cause neonatal respiratory depression.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Neonatal hypocalcaemia</ph> or <ph outputclass="indication">Hypomagnesaemia</ph> or <ph outputclass="indication">Torsade de pointes</ph> or <ph outputclass="indication">Severe acute asthma</ph> or <ph outputclass="indication">Continuing respiratory deterioration in anaphylaxis</ph> in children</p>
          <p>Sufficient amount may cross the placenta in mothers treated with high doses e.g. in pre-eclampsia, causing hypotonia and respiratory depression in newborns.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInPregnancy">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Pregnant women with fluid retention should be monitored closely.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47586" outputclass="breastFeeding">
    <title>Breast feeding</title>
    <body>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Use with caution during breast-feeding.</p>
          <p>Amount too small to be harmful but some manufacturers advise avoid (including topical use).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Use with caution during breast-feeding.</p>
          <p>Amount too small to be harmful but some manufacturers advise avoid.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Patient packs for topical preparations carry a warning to avoid during breast-feeding.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInBreastFeeding">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>Infant should be monitored for adrenal suppression if mother is taking a dose higher than 40 mg.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47485" outputclass="hepaticImpairment">
    <title>Hepatic impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</p>
          <p>Reduce dose.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p>
          <p>Avoid in severe liver disease.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInHepaticImpairment">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use or <ph outputclass="route">oral</ph> use</p>
          <p>Monitor plasma-chloramphenicol concentration in hepatic impairment.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47360" outputclass="renalImpairment">
    <title>Renal impairment</title>
    <body>
      <section outputclass="doseAdjustments">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Use lowest effective dose.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>The lowest effective dose should be used for the shortest possible duration.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>The lowest effective dose should be used for the shortest possible duration.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalInformation">
        <sectiondiv>
          <p>Use with caution in renal impairment— increased risk of lactic acidosis.</p>
          <sectiondiv>
            <p outputclass="title">Lactic acidosis</p>
            <p>Withdraw or interrupt treatment in those at risk of tissue hypoxia or sudden deterioration in renal function, such as those with dehydration, severe infection, shock, sepsis, acute heart failure, respiratory failure or hepatic impairment, or those who have recently had a myocardial infarction.</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In adults</p>
          <p>NICE (clinical guideline 87 (May 2009): Type 2 diabetes: The management of type 2 diabetes) recommends that the dose should be reviewed if eGFR less than 45 mL/minute/1.73 m<sup>2</sup> and to avoid if eGFR less than 30 mL/minute/1.73 m<sup>2</sup>.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p>Avoid in significant renal impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Avoid if possible in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use in adults</p>
          <p>Avoid if possible or use with caution.</p>
          <p>Avoid in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use in children</p>
          <p>Avoid if possible or use with caution.</p>
          <p>Avoid in severe impairment.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Deterioration in renal function has also been reported after topical use.</p>
        </sectiondiv>
      </section>
      <section outputclass="additionalMonitoringInRenalImpairment">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">systemic</ph> use</p>
          <p>In renal impairment monitor renal function; sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP72393" outputclass="monitoringRequirements">
    <title>Monitoring requirements</title>
    <body>
      <section outputclass="patientMonitoringProgrammes">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p>Gynaecological examination before insertion, 4–6 weeks after insertion, then annually.</p>
        </sectiondiv>
      </section>
      <section outputclass="therapeuticDrugMonitoring">
        <sectiondiv>
          <p>All patients require plasma-vancomycin measurement (after 3 or 4 doses if renal function normal, earlier if renal impairment).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Pre-dose (‘trough’) concentration should be 10–15 mg/litre (15–20 mg/litre for endocarditis or less sensitive strains of meticillin-resistant <ph outputclass="organism"><i>Staphylococcus aureus</i></ph> or for complicated infections caused by <ph outputclass="organism"><i>S. aureus</i></ph>). An initial loading dose, by intravenous infusion, may be considered—consult local guidelines.</p>
        </sectiondiv>
      </section>
      <section outputclass="monitoringOfPatientParameters">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>Monitor for bleeding.</p>
          <p>Monitor gastro-intestinal function.</p>
        </sectiondiv>
        <sectiondiv>
          <p>In view of reports of blood dyscrasias (including fatalities) and liver cirrhosis with low-dose methotrexate patients should:</p>
          <ul>
            <li>have full blood count and renal and liver function tests repeated every 1–2 weeks until therapy stabilised, thereafter patients should be monitored every 2–3 months.</li>
            <li>be advised to report all symptoms and signs suggestive of infection, especially sore throat<p>Local protocols for frequency of monitoring may vary.</p><p>Treatment with folinic acid (as calcium folinate) may be required in acute toxicity.</p></li>
          </ul>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47614" outputclass="directionsForAdministration" rev="1.15">
    <title>Directions for administration</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</p>
          <p>For <i>slow intravenous injection</i>, give over 15 minutes, preferably undiluted. May be diluted with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>For topical preparations, apply with gentle massage only.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP60842" outputclass="prescribingAndDispensingInformation" rev="1.29">
    <title>Prescribing and dispensing information</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Flavours of syrup may include orange.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in children</p>
          <p>Caution—topical preparations not generally suitable for children.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Not recommended for diarrhoea associated with invasive organisms such as <ph outputclass="organism"><i>Campylobacter</i></ph> and <ph outputclass="organism"><i>Shigella</i></ph>.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP58801" outputclass="treatmentCessation" rev="1.15">
    <title>Treatment cessation</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used for <ph outputclass="indication">Pulmonary arterial hypertension</ph></p>
          <p>Consider gradual withdrawal.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47383" outputclass="patientAndCarerAdvice" rev="1.22">
    <title>Patient and carer advice</title>
    <body>
      <section outputclass="patientResources">
        <sectiondiv>
          <p outputclass="specificity">In children</p>
          <p outputclass="title">Medicines for Children leaflet: Ibuprofen for pain and inflammation</p>
          <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation">www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation</xref>
          </p>
        </sectiondiv>
      </section>
      <section outputclass="adviceAroundMissedDoses">
        <title>Missed doses</title>
        <sectiondiv>
          <p>When used as an oral contraceptive, the following advice is recommended ‘If you forget a pill, take it as soon as you remember and carry on with the next pill at the right time. If the pill was more than 3 hours overdue you are not protected. Continue normal pill-taking but you must also use another method, such as the condom, for the next 2 days’.</p>
          <p>The Faculty of Sexual and Reproductive Healthcare recommends emergency contraception if one or more progestogen-only contraceptive tablets are missed or taken more than 3 hours late and unprotected intercourse has occurred before 2 further tablets have been correctly taken.</p>
        </sectiondiv>
      </section>
      <section outputclass="adviceAroundDrivingAndOtherTasks">
        <title>Driving and skilled tasks</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Dizziness and somnolence may affect the performance of skilled tasks (e.g. driving).</p>
        </sectiondiv>
      </section>
      <section outputclass="generalPatientAdvice">
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>For topical preparations, patients and their carers should be advised to wash hands immediately after use.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p outputclass="title">Photosensitivity</p>
          <p>For topical preparations, patients or their carers should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="title">Diarrhoea and vomiting with use as an oral contraceptive</p>
          <p>Vomiting and persistent, severe diarrhoea can interfere with the absorption of oral progestogen-only contraceptives. If vomiting occurs within 2 hours of taking an oral progestogen-only contraceptive, another pill should be taken as soon as possible. If a replacement pill is not taken within 3 hours of the normal time for taking the progestogen-only pill, or in cases of persistent vomiting or very severe diarrhoea, additional precautions should be used during illness and for 2 days after recovery.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Contraception</ph></p>
          <p outputclass="title">Starting routine</p>
          <p>One tablet daily, on a continuous basis, starting on day 1 of cycle and taken at the same time each day (if delayed by longer than 3 hours contraceptive protection may be lost). Additional contraceptive precautions are not necessary when initiating treatment.</p>
          <sectiondiv>
            <p outputclass="title">Changing from a combined oral contraceptive</p>
            <p>Start on the day following completion of the combined oral contraceptive course without a break (or in the case of ED tablets omitting the inactive ones).</p>
          </sectiondiv>
          <sectiondiv>
            <p outputclass="title">After childbirth</p>
            <p>Oral progestogen-only contraceptives can be started up to and including day 21 postpartum without the need for additional contraceptive precautions. If started more than 21 days postpartum, additional contraceptive precautions are required for 2 days.</p>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intra-uterine</ph> use</p>
          <p>Counsel women to seek medical attention promptly in case of significant symptoms, especially pain.</p>
          <p>Patient counselling advised.</p>
          <p>Patient information leaflet to be provided.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></p>
          <p>If vomiting occurs within 2 hours of taking levonorgestrel, a replacement dose should be given.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use for <ph outputclass="indication">Emergency contraception</ph></p>
          <ul>
            <li>When prescribing or supplying hormonal emergency contraception, women should be advised:</li>
            <li>that their next period may be early or late;</li>
            <li>that a barrier method of contraception needs to be used until the next period;</li>
            <li>to seek medical attention promptly if any lower abdominal pain occurs because this could signify an ectopic pregnancy;</li>
            <li>to return in 3 to 4 weeks if the subsequent menstrual bleed is abnormally light, heavy or brief, or is absent, or if she is otherwise concerned (if there is any doubt as to whether menstruation has occurred, a pregnancy test should be performed at least 3 weeks after unprotected intercourse).</li>
          </ul>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47285" outputclass="professionSpecificInformation" rev="1.17">
    <title>Profession specific information</title>
    <body>
      <section outputclass="dentalPractitionersFormulary">
        <title>Dental practitioners' formulary</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Ibuprofen Oral Suspension Sugar-free may be prescribed.</p>
          <p>Ibuprofen Tablets may be prescribed.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP64201" outputclass="nationalFunding" rev="1.14">
    <title>National funding/access decisions</title>
    <body>
      <section outputclass="nonNHS">
        <title>NHS restrictions</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Fungal skin infections</ph></p>
          <p>Ketoconazole cream is not prescribable on the NHS except for seborrhoeic dermatitis and pityriasis versicolor and endorsed 'SLS'.</p>
        </sectiondiv>
      </section>
      <section>
        <sectiondiv outputclass="niceTechnologyAppraisals">
          <p outputclass="title">NICE technology appraisals (TAs)</p>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA337</p>
            <sectiondiv>
              <p outputclass="title">Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015)</p>
              <p>Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in adults.</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA337">www.nice.org.uk/TA337</xref>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="niceTechnologyAppraisals">
          <p outputclass="title">NICE technology appraisals (TAs)</p>
          <sectiondiv outputclass="niceTechnologyAppraisal">
            <p outputclass="fundingIdentifier">NICE TA276</p>
            <sectiondiv>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
              <p outputclass="title">Tobramycin by dry powder inhalation for pseudomonal lung infection in cystic fibrosis (March 2013)</p>
              <p>Tobramycin dry powder for inhalation is recommended for chronic pulmonary infection caused by <ph outputclass="organism"><i>Pseudomonas aeruginosa</i></ph> in patients with cystic fibrosis only if there is an inadequate response to colistimethate sodium, or if colistimethate sodium cannot be used because of contra-indications or intolerance. The manufacturer must provide tobramycin dry powder for inhalation at the discount agreed as part of the patient access scheme to primary, secondary and tertiary care in the NHS.</p>
              <p>Patients currently receiving tobramycin dry powder for inhalation can continue treatment until they and their clinician consider it appropriate to stop.</p>
            </sectiondiv>
            <xref format="html" href="http://www.nice.org.uk/TA276">www.nice.org.uk/TA276</xref>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="smcDecisions">
          <p outputclass="title">Scottish Medicines Consortium (SMC) Decisions</p>
          <sectiondiv outputclass="smcDecision">
            <sectiondiv>
              <p>The <i>Scottish Medicines Consortium</i> has advised (February 2011) that dalteparin (<i>Fragmin</i><ph outputclass="sc"><tm tmtype="reg" /></ph>) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
        <sectiondiv outputclass="smcDecisions">
          <p outputclass="title">Scottish Medicines Consortium (SMC) Decisions</p>
          <sectiondiv outputclass="smcDecision">
            <sectiondiv>
              <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
              <p>The <i>Scottish Medicines Consortium</i> has advised (March 2014) that fluticasone furoate/vilanterol (<i>Relvar Ellipta</i><tm tmtype="reg" />) is accepted for restricted use within NHS Scotland in patients with severe chronic obstructive pulmonary disease with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 50% of the predicted normal value.</p>
            </sectiondiv>
          </sectiondiv>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP47272" outputclass="exceptionsToLegalCategory" rev="1.15">
    <title>Exceptions to legal category</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use in adults</p>
          <p>Smaller pack sizes of gel preparations may be available on sale to the public.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">oral</ph> use</p>
          <p>Azithromycin tablets can be sold to the public for the treatment of confirmed, asymptomatic <ph outputclass="organism"><i>Chlamydia trachomatis</i></ph> genital infection in those over 16 years of age, and for the epidemiological treatment of their sexual partners, subject to maximum single dose of 1 g, maximum daily dose 1 g, and a pack size of 1 g.</p>
        </sectiondiv>
        <sectiondiv>
          <p>
            <i>Levonelle</i>
            <tm tmtype="reg" />
            <i>One Step</i> can be sold to women over 16 years; when supplying emergency contraception to the public, pharmacists should refer to guidance issued by the Royal Pharmaceutical Society.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Fungal skin infections</ph> in adults</p>
          <p>A 15-g tube is available for sale to the public for the treatment of tinea pedis, tinea cruris, and candidal intertrigo.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use for <ph outputclass="indication">Seborrhoeic dermatitis and dandruff</ph></p>
          <p>Can be sold to the public for the prevention and treatment of dandruff and seborrhoeic dermatitis of the scalp as a shampoo formulation containing ketoconazole maximum 2%, in a pack containing maximum 120 mL and labelled to show a maximum frequency of application of once every 3 days.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP34872" outputclass="patientAndCarerAdvice" rev="1.54">
    <title>Patient and carer advice</title>
    <body>
      <section outputclass="patientResources">
        <sectiondiv>
          <p outputclass="title">Methotrexate treatment booklets</p>
          <p>Methotrexate treatment booklets should be issued where appropriate.</p>
          <p>In <b>England</b>, <b>Wales</b>, and <b>Northern Ireland</b>, they are available for purchase from:</p>
          <ul outputclass="organization">
            <li outputclass="thoroughfare">Gorse Street, Chadderton</li>
            <li outputclass="localityname">Oldham</li>
            <li outputclass="postalcode">OL9 9QH</li>
            <li outputclass="contactnumber">Tel: 0845 610 1112</li>
          </ul>
          <p>GP practices can obtain supplies through their Local Area Team stores. </p>
          <p>NHS Hospitals can order supplies from <xref format="html" href="http://www.nhsforms.co.uk">www.nhsforms.co.uk</xref></p>
          <p>or by emailing nhsforms@mmm.com.</p>
          <p>In <b>Scotland</b>, treatment booklets can be obtained by emailing stockorders.dppas@theapsgroup.com or by fax on 0131 629 9967.</p>
          <p>These booklets include advice for adults taking oral methotrexate for inflammatory conditions, and a section for recording results of blood tests and dosage information.</p>
        </sectiondiv>
      </section>
      <section outputclass="generalPatientAdvice">
        <sectiondiv>
          <p>Patients should be advised to avoid self-medication with over-the-counter aspirin or ibuprofen.</p>
          <p>Patients should be counselled on the dose, treatment booklet, and the use of NSAIDs.</p>
        </sectiondiv>
        <sectiondiv>
          <p>Patients and their carers should be warned to report immediately the onset of any feature of blood disorders (e.g. sore throat, bruising, and mouth ulcers), liver toxicity (e.g. nausea, vomiting, abdominal discomfort and dark urine), and respiratory effects (e.g. shortness of breath).</p>
        </sectiondiv>
      </section>
      <section outputclass="adviceAroundMissedDoses">
        <title>Missed doses</title>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intramuscular</ph> use</p>
          <p>For missed doses see product literature.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP41817" outputclass="preTreatmentScreening" rev="1.11">
    <title>Pre-treatment screening</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">inhalation</ph></p>
          <p>Patients must be assessed for bronchial hyperresponsiveness to inhaled mannitol before starting the therapeutic dose regimen; an initiation dose assessment must be carried out under medical supervision—for details of the initiation dose regimen, consult product literature.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intravenous</ph> use</p>
          <p>Assess cardiac function before treatment.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP69402" outputclass="effectOnLaboratoryTests" rev="1.12">
    <title>Effect on laboratory tests</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use</p>
          <p>May interfere with thyroid function tests.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP58881" outputclass="handlingAndStorage" rev="1.8">
    <title>Handling and storage</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">topical</ph> use</p>
          <p>Wash hands immediately after use (or wash hands 30 minutes after application if hands treated).</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">transdermal</ph> use</p>
          <p>Nitrile gloves to be worn while handling patches and cleaning treatment areas (latex gloves do not provide adequate protection).</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP89072" outputclass="lessSuitableForPrescribing" rev="1.18">
    <title>Less suitable for prescribing</title>
    <body>
      <section>
        <sectiondiv>
          <p outputclass="specificity">When used by <ph outputclass="route">eye</ph></p>
          <p>Betamethsone with neomycin eye-drops are less suitable for prescribing.</p>
        </sectiondiv>
        <sectiondiv>
          <p outputclass="specificity">With <ph outputclass="route">intranasal</ph> use</p>
          <p>Betamethsone with neomycin nasal-drops are less suitable for prescribing; there is no evidence that topical anti-infective nasal preparations have any therapeutic value in rhinitis or sinusitis.</p>
        </sectiondiv>
      </section>
    </body>
  </topic>
  <topic id="PHP6461-medicinalForms" outputclass="medicinalForms">
    <title>Medicinal forms</title>
    <body>
      <section outputclass="licensingVariationStatement">
        <p>There can be variation in the licensing of different medicines containing the same drug.</p>
      </section>
      <p>Forms available from special-order manufacturers include: oral suspension</p>
    </body>
    <xref href="PHP77419.xml" rel="medicinalForm">Tablet</xref>
    <xref href="PHP77372.xml" rel="medicinalForm">Orodispersible tablet</xref>
    <xref href="PHP77359.xml" rel="medicinalForm">Modified-release tablet</xref>
    <xref href="PHP77409.xml" rel="medicinalForm">Capsule</xref>
    <xref href="PHP77385.xml" rel="medicinalForm">Modified-release capsule</xref>
    <xref href="PHP77365.xml" rel="medicinalForm">Effervescent granules</xref>
    <xref href="PHP77413.xml" rel="medicinalForm">Oral suspension</xref>
    <xref href="PHP77400.xml" rel="medicinalForm">Solution for infusion</xref>
    <xref href="PHP77392.xml" rel="medicinalForm">Foam</xref>
    <xref href="PHP77344.xml" rel="medicinalForm">Gel</xref>
    <xref href="PHP77351.xml" rel="medicinalForm">Spray</xref>
    <xref href="PHP77428.xml" rel="medicinalForm">Powder</xref>
  </topic>
</topic>
</sample>
